<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oral Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">J Oral Microbiol</journal-id><journal-title-group><journal-title>Journal of Oral Microbiology</journal-title></journal-title-group><issn pub-type="epub">2000-2297</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013014</article-id><article-id pub-id-type="pmc">PMC11864011</article-id><article-id pub-id-type="doi">10.1080/20002297.2025.2469890</article-id><article-id pub-id-type="publisher-id">2469890</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Oral bacteriophages and their potential as adjunctive treatments for periodontitis: a narrative review</article-title><alt-title alt-title-type="left-running-head">M. KABWE ET AL.</alt-title><alt-title alt-title-type="right-running-head">JOURNAL OF ORAL MICROBIOLOGY</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kabwe</surname><given-names>Mwila</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tucci</surname><given-names>Joseph</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Darby</surname><given-names>Ivan</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0106-8691</contrib-id><name><surname>Dashper</surname><given-names>Stuart</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label>Department of Rural Clinical Sciences, La Trobe Rural Health School &#x00026; La Trobe Institute for Molecular Science, <institution-wrap><institution>La Trobe University</institution></institution-wrap>, <city>Bendigo</city>, <state>Victoria</state>, <country>Australia</country></aff><aff id="aff0002"><label>b</label>Melbourne Dental School, <institution-wrap><institution>University of Melbourne</institution></institution-wrap>, <city>Parkville</city>, <state>Victoria</state>, <country>Australia</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Stuart Dashper <email xlink:href="mailto:stuartgd@unimelb.edu.au">stuartgd@unimelb.edu.au</email> Melbourne Dental School, Faculty of Medicine, Dentistry &#x00026; Health Sciences, The University of Melbourne, <city>Parkville</city>, <state>Victoria</state>
<postal-code>3010</postal-code>, <country>Australia</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><elocation-id seq="16">2469890</elocation-id><pub-history><event event-type="tagger"><event-desc>Integra</event-desc><date><day>25</day><month>2</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>25</day><month>2</month><year>2025</year></date></event><event event-type="received"><date><day>23</day><month>12</month><year>2024</year></date></event><event event-type="revised"><date><day>29</day><month>1</month><year>2025</year></date></event><event event-type="accepted"><date><day>31</day><month>1</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ZJOM_17_2469890.pdf"/><abstract><title>ABSTRACT</title><sec><title>Background</title><p>There is no specific cure for periodontitis and treatment is symptomatic, primarily by physical removal of the subgingival plaque biofilm. Current non-surgical periodontal therapy becomes less effective as the periodontal pocket depth increases and as such new adjunctive treatments are required. The development of antibiotic resistance has driven a recent resurgence of interest in bacteriophage therapy.</p></sec><sec><title>Methods</title><p>Here we review the published literature with a focus on the subgingival phageome, key oral pathobionts and the dysbiotic nature of periodontitis leading to the emergence of synergistic, proteolytic and inflammophilic bacterial species in subgingival plaque. We discuss the opportunities available, the barriers and the steps needed to develop bacteriophage therapy as an adjunctive treatment for periodontitis.</p></sec><sec><title>Results</title><p>The oral phageome (or virome) is diverse, featuring abundant bacteriophage, that could target key subgingival bacteria. Yet to date few bacteriophages have been isolated and characterised from oral bacterial species, although many more have been predicted by genomic analyses. Bacteriophage therapy has yet to be tested against chronic diseases that are caused by dysbiosis of the endogenous microbial communities.</p></sec><sec><title>Conclusion</title><p>To be effective as an adjunctive treatment for periodontitis, bacteriophage therapy must cause the collapse of the dysbiotic bacterial community, thereby resolving inflammation and enabling the reestablishment of a health-associated mutualistic subgingival bacterial community. The isolation and characterisation of novel oral bacteriophage is an essential first step in this process.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>KEY MESSAGES</title><p>
<list list-type="order"><list-item><p>The oral phageome is still poorly described and characterised especially with regard to lytic bacteriophage.</p></list-item><list-item><p>Bacteriophage therapy has yet to be applied to any chronic human disease caused by microbial dysbiosis.</p></list-item><list-item><p>Despite many challenges bacteriophage therapy offers the potential to be a safe, specific and efficacious adjunctive treatment for periodontitis.</p></list-item></list></p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd><italic toggle="yes">Fusobacterium nucleatum</italic></kwd><kwd>dysbiosis</kwd><kwd><italic toggle="yes">Treponema denticola</italic></kwd><kwd><italic toggle="yes">Porphyromonas gingivalis</italic></kwd><kwd>phage therapy</kwd></kwd-group><support-group><funding-group><funding-statement>The author(s) reported there is no funding associated with the work featured in this article.</funding-statement></funding-group></support-group><counts><fig-count count="4"/><table-count count="1"/><ref-count count="154"/><page-count count="1"/><word-count count="7261"/></counts></article-meta></front><body><sec disp-level="1" id="s0001"><title>Periodontitis</title><p>Periodontitis, formerly described as chronic periodontitis, is a bacterial induced inflammatory disease of the supporting tissues of the tooth that is characterised by the progressive destruction of those tissues and is regarded as the most common chronic inflammatory, non-communicable human disease. The Global Burden of Disease 2010 study reported the global age-standardized prevalence (1990&#x02013;2010) of severe periodontitis to be 10.5&#x02013;12.0%, representing the sixth-most prevalent condition in the world [<xref rid="cit0001" ref-type="bibr">1</xref>]. Moderate-to-severe forms of periodontitis affect approximately 30% of adults [<xref rid="cit0002" ref-type="bibr">2</xref>], whilst the prevalence of all forms including milder disease may be as high as 50% [<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0003" ref-type="bibr">3</xref>]. Periodontitis is characterised by loss of the supporting structures of the teeth, and is diagnosed using clinical attachment loss (CAL) and alveolar bone loss, the presence of periodontal pocketing and gingival bleeding [<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref>]. Diagnosis is made after destruction.</p><p>Although periodontitis is largely preventable and controllable in the majority of cases, if untreated, it can lead to tooth loss and impaired quality of life [<xref rid="cit0006" ref-type="bibr">6</xref>]. Periodontitis is a chronic disease that progresses over years, during which time, the diseased supra- and sub-gingival epithelia are exposed to heavy bacterial loads. With increasing disease severity, periodontitis can become a significant source of systemic as well as localised inflammation and a source of persistent bacteraemia. The disease has been linked to an increased risk of diabetes, cardiovascular diseases, certain cancers, pre-term birth, rheumatoid arthritis and Alzheimer&#x02019;s disease [<xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref>].</p><p>In 2018, the direct costs of periodontitis were estimated to be US$3.5 billion in the US and &#x020ac;2.5 billion in Europe. Indirect costs resulting from periodontitis were US$150 billion in the US and &#x020ac;156 billion in European countries [<xref rid="cit0009" ref-type="bibr">9</xref>]. These data indicate that periodontitis is a major public health problem globally with a substantial economic and social burden.</p></sec><sec disp-level="1" id="s0002"><title>Current treatments</title><p>There is no specific cure for periodontitis to address the underlying microbial cause and treatment is symptomatic. The recent Clinical Practice Guidelines, developed under the auspices of the European Federation of Periodontology, recommend that initial clinical treatment of periodontitis should be subgingival instrumentation (also known as non-surgical mechanical debridement or scaling and root planning). This is aimed at reducing the subgingival plaque biofilm and calculus, leading to a reduction in probing pocket depths, gingival inflammation and the number of diseased sites [<xref rid="cit0005" ref-type="bibr">5</xref>]. This therapy is recommended for all periodontitis patients, irrespective of their disease severity, for those teeth with loss of periodontal tissue support and/or periodontal pocket formation. In patients who are motivated to maintain a high level of oral hygiene, this treatment can result in long-term periodontal stability [<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref>]. However, depending upon the evaluation criteria used, up to 40% of diseased sites may not respond well to treatment [<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0013" ref-type="bibr">13</xref>]. Factors that contribute to a failure of treatment include residual calculus and anatomical features of the site that limit accessibility to the tooth root preventing thorough plaque removal [<xref rid="cit0014" ref-type="bibr">14&#x02013;16</xref>]. In general, subgenival instrumentation becomes less effective as the periodontal pocket depth increases [<xref rid="cit0017" ref-type="bibr">17&#x02013;19</xref>]. In these sites, Retamal-Valdes <italic toggle="yes">et al.</italic> [<xref rid="cit0020" ref-type="bibr">20</xref>] concluded that subgingival instrumentation alone was unable to produce a sufficiently significant change in the oral microbial ecology in order to produce a new stable climax biofilm community compatible with periodontal health. Therefore, a range of adjunctive therapies has been proposed with the purpose of potentiating the effects of subgingival instrumentation.</p><p>Sanz <italic toggle="yes">et al.</italic> [<xref rid="cit0005" ref-type="bibr">5</xref>] evaluated the adjunctive interventions to subgingival instrumentation, including: physical or chemical agents, host-modulating agents (local or systemic), subgingival locally delivered antimicrobials, or systemic antimicrobials. Of 12 specific adjunctive treatments the panel considered, the only ones they cautiously recommended were some of those that modulated the bacterial components of the subgingival plaque. The panel consensus was to not recommend the use of nine adjunctive treatments, namely photodynamic therapy or lasers, local administration of statin gels (atorvastatin, simvastatin, rosuvastatin), probiotics, systemic sub-antimicrobial dose doxycycline, locally delivered bisphosphonate gels or systemic bisphosphonates, systemic or local non-steroidal anti-inflammatory drugs, omega&#x02212;3 polyunsaturated fatty acids, and local administration of metformin gel; due to lack of evidence regarding efficacy or a cost to benefit analysis. The use of adjunctive antiseptics, specifically chlorhexidine mouth rinses for a limited period of time, and locally administered sustained-release antibiotics was recommended for consideration. However, these have a number of side effects that may prevent long-term use, such as staining. Although the combination of metronidazole and amoxicillin has been consistently shown to offer significant clinical and microbiological benefits as an adjunctive treatment [<xref rid="cit0021" ref-type="bibr">21</xref>] due to concerns about the patient&#x02019;s broader health and the impact of systemic antibiotic use to public health, its use as a routine adjunct to subgingival debridement in patients with periodontitis was not recommended [<xref rid="cit0005" ref-type="bibr">5</xref>].</p><p>Management of periodontal disease is more than just initial removal of bacterial deposits, but occurs over the long term, i.e many years. Maintenance of improvements in periodontal health and prevention of breakdown are managed by regular recall appointments and supportive periodontal therapy. These appointments involve removing the biofilm that has accumulated between visits and motivating patients to continue or improve their oral hygiene. Even within a maintenance program there can be continued progression and attendance at these appointments decreases over.</p><p>Given the failure of up to 40% of sites to respond well to subgingival instrumentation, the chronic nature of the disease and the current lack of specific and acceptable adjunctive treatments there is clearly a need for development of novel adjunctive treatments that address the root cause of periodontitis, subgingival plaque bacterial community structure and composition. The manipulation of periodontal microbiota has the potential to serve as an adjunct or an alternative to conventional mechanical periodontal therapy [<xref rid="cit0022" ref-type="bibr">22</xref>]. The goal of this adjunctive treatment would be to tip the balance in favour of the re-establishment of eubiotic health-associated communities [<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref>]. This adjunctive treatment would need to be specific and not target bacterial species associated with health. A recent small clinical trial of the probiotic <italic toggle="yes">Lactobacillus reuteri</italic> has shown some potential as an adjunctive treatment in periodontitis possibly due to its ability to inhibit pathogenic community reformation and its anti-inflammatory properties [<xref rid="cit0024" ref-type="bibr">24</xref>]. Bacteriophage therapy (below) offers the potential for high specificity targeting of key pathobionts with no known side effects.</p></sec><sec disp-level="1" id="s0003"><title>Microbiology of periodontitis</title><p>The microbial aetiology of periodontitis is complex. Periodontitis is a site-specific inflammatory disease that is now widely accepted to be caused by
a microbial dysbiosis in subgingival plaque biofilms. This results in the emergence of a limited number of pathobionts, oral bacteria that exist in the oral cavity during health but under specific environmental conditions induce chronic disease [<xref rid="cit0025" ref-type="bibr">25</xref>]. These pathobionts, including <italic toggle="yes">Porphyromonas gingivalis, Treponema denticola, Fusobacterium nucleatum</italic>, <italic toggle="yes">Filifacter alocis</italic> and <italic toggle="yes">Tannerella forsythia</italic>, come to dominate the bacterial community of subgingival plaque at the base of the periodontal pocket (<xref rid="f0001" ref-type="fig">Figure 1</xref>). They increase substantially in the subgingival plaque biofilm prior to tissue breakdown and alone can exceed 25% of the subgingival plaque microbiota [<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0023" ref-type="bibr">23</xref>]. There is also a large increase in the number of bacteria in the subgingival sites due to the expansion of the site, and the increased flow of nutrients. In addition, the neutralisation of an effective host response also favours bacterial proliferation.
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1.</label><caption><p>The major health and periodontitis-associated oral bacterial species found in subgingival plaque. The data was derived from analysis of seven individual studies and the number of asterisks refers to the number of studies that identified the health or disease association of each species. Reprinted from Balan et al. [<xref rid="cit0022" ref-type="bibr">22</xref>].</p></caption><alternatives><graphic xlink:href="ZJOM_A_2469890_F0001_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="ZJOM_A_2469890_F0001_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>There is still considerable discussion in the scientific literature around the importance of specific bacterial species to the development of the dysbiotic bacterial community associated with periodontitis with, for example, <italic toggle="yes">P. gingivalis</italic> having been described at various times as an opportunistic pathogen [<xref rid="cit0026" ref-type="bibr">26</xref>], a key component, along with <italic toggle="yes">Treponema denticola</italic>, <italic toggle="yes">Tannerella forsythia</italic> of the disease-associated Red Complex [<xref rid="cit0027" ref-type="bibr">27</xref>], a keystone pathogen [<xref rid="cit0028" ref-type="bibr">28</xref>,<xref rid="cit0029" ref-type="bibr">29</xref>] and now as part of the pathogenic dysbiotic subgingival bacterial community [<xref rid="cit0030" ref-type="bibr">30</xref>].</p><p>Bacterial interactions within a dysbiotic community are proposed to be fundamental processes affecting chronic human disease initiation, progression, severity, susceptibility to antimicrobial therapy and resolution. These polymicrobial biofilm communities consist of multiple cells cooperating to build a differentiated structure, and as such exhibit the emergent characteristics of multicellular organisms. Within polymicrobial biofilms particular species have specialised functions and different metabolic rates associated with specific developmental profiles [<xref rid="cit0031" ref-type="bibr">31</xref>]. This is especially true of oral polymicrobial biofilms that can be very complex and long lived. Specialisation is needed for bacteria to build complex biofilms due to the relatively limited size of bacterial genomes. One of the defining features of complex polymicrobial biofilms is the production of an extracellular matrix that can act not only to protect biofilm cells from environmental stressors but can also provide a defined structure and help to spatially locate particular species within the biofilm. A small number of recent studies indicate that micron-scale spatial structures resulting from interspecies bacterial adhesion and metabolic interactions are key determinants of the function of polymicrobial biofilm communities [<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref>]. The tools to further define these spatial structures are now being developed which will enable these observations to be further characterised [<xref rid="cit0034" ref-type="bibr">34</xref>]. With regard to periodontitis species such as <italic toggle="yes">Fusobacterium nucleatum</italic> and <italic toggle="yes">Streptococcus gordonii</italic> are thought to enable pathogenic plaque community development acting as scaffolding and symbiotic partners [<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0036" ref-type="bibr">36</xref>], although <italic toggle="yes">F. nucleatum</italic> may also play a direct role in disease progression. Sakanaka <italic toggle="yes">et al.</italic> [<xref rid="cit0037" ref-type="bibr">37</xref>] have recently shown <italic toggle="yes">F. nucleatum</italic> produces putrescine from arginine via ornithine that accelerates the biofilm life cycle of <italic toggle="yes">P. gingivalis</italic>. Similarly, <italic toggle="yes">P. gingivalis</italic> has been shown to release diffusible signals that enhance <italic toggle="yes">F. nucleatum</italic> biofilm development [<xref rid="cit0038" ref-type="bibr">38</xref>]. These types of cooperative metabolism within oral biofilms can tip the balance toward periodontitis [<xref rid="cit0037" ref-type="bibr">37</xref>]. Indeed, <italic toggle="yes">F. nucleatum</italic> may be seen as a keystone species in dysbiotic community development due to its ability to coaggregate widely with both early colonising health associated species and species associated with disease, and its flexible metabolic capabilities, although this remains to be tested [<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>]. More of the fundamental metabolic processes underpinning subgingival bacterial community development and stability are now being characterised at least between a limited number of species in these communities. <italic toggle="yes">Streptococcus gordonii</italic> for example has been proposed as important for the colonisation of a site and persistence of <italic toggle="yes">P. gingivalis</italic>, especially in health, due to its syntrophic ability, symbiotic biofilm formation and protection from oxidative stress [<xref rid="cit0036" ref-type="bibr">36</xref>]. Syntrophic interactions and avoidance of substrate competition between <italic toggle="yes">P. gingivalis</italic> and <italic toggle="yes">T. denticola</italic> have been shown to greatly increase biomass when the species are co-cultured [<xref rid="cit0039" ref-type="bibr">39</xref>]. The motility of <italic toggle="yes">T. denticola</italic> along with the metabolic interactions have been shown to play crucial roles in polymicrobial biofilm development with <italic toggle="yes">P. gingivalis</italic> [<xref rid="cit0040" ref-type="bibr">40&#x02013;42</xref>].</p><p>This dysbiotic community works collaboratively and symbiotically to cause host inflammation, dysregulate that response and subvert it to provide a range of macro- and micro-nutrients (<xref rid="f0002" ref-type="fig">Figure 2</xref>). Although there is likely to be some redundancy in this community, the removal of a small number of species may have broader implications on the whole community. The ability to disrupt the micron-scale spatial structures of these disease-associated communities by targeting key species involved in community physical structure or in essential metabolic processes offers the potential to collapse these communities and may enable the re-establishment of health associated communities. This contention has not been widely tested due to the lack of specific agents that can selectively remove single species from dysbiotic communities and the use of specific agents, such as bacteriophages, could greatly improve our understanding of the dynamics of these bacterial communities. Oxantel pamoate, which has no effect on <italic toggle="yes">T. denticola</italic>, was shown to collapse polymicrobial biofilm development with <italic toggle="yes">P. gingivalis</italic> and <italic toggle="yes">T. forsythia</italic> inhibiting all three
species to a similar degree, demonstrating the synergistic nature of biofilm development by these species and the dependence of <italic toggle="yes">T. denticola</italic> on the other two [<xref rid="cit0044" ref-type="bibr">44</xref>]. In actively progressing periodontal pockets <italic toggle="yes">F. nucleatum</italic> was the most abundant bacterial taxa at a species level, followed by <italic toggle="yes">P. gingivalis</italic> and <italic toggle="yes">T. denticola</italic>. All these species decreased significantly in abundance in those sites that responded to treatment but remained high in those sites that did not respond to treatment (<xref rid="f0003" ref-type="fig">Figure 3</xref> [<xref rid="cit0023" ref-type="bibr">23</xref>]).
<fig position="float" id="f0002" fig-type="figure"><label>Figure 2.</label><caption><p>Development of a dysbiotic subgingival plaque community during periodontitis. The dysbiotic microbial community which is characterized by an increase in abundance of a small number of pathobionts stimulates local host inflammatory responses. Inflammation results in tissue breakdown that produces nutrients, including peptides, haem and ferrous iron, further facilitating the proliferation of inflammophilic pathobionts. The unresolved inflammation deepens periodontal pockets providing more suitable habitat for pathobionts. Reprinted with permission from Liu et al. [<xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>].</p></caption><alternatives><graphic xlink:href="ZJOM_A_2469890_F0002_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="ZJOM_A_2469890_F0002_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig>
<fig position="float" id="f0003" fig-type="figure"><label>Figure 3.</label><caption><p>Differences in the relative abundances of the 25 most abundant bacterial taxa at a species level in subgingival plaque prior to and in response to non-surgical debridement treatment in sites with no response (NR) and matched good responding (GR) sites. Subgingival plaque samples were taken just prior to treatment (0&#x02009;m) and three months after treatment (3&#x02009;m). The x-axis depicts the relative change in abundance as a percentage of the total. Reprinted with permission from Byrne et al. [<xref rid="cit0023" ref-type="bibr">23</xref>].</p></caption><alternatives><graphic xlink:href="ZJOM_A_2469890_F0003_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="ZJOM_A_2469890_F0003_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>The establishment of pathogenic bacterial communities in periodontal pockets that are closely associated with an ulcerated epithelial layer enables these bacteria and their products to enter the bloodstream and circulate to distal parts of the body. <italic toggle="yes">F. nucleatum</italic> and <italic toggle="yes">P. gingivalis</italic> are now referred to as oncobacteria, that have been linked to the development, metastasis and chemotherapy resistance of oropharyngeal, pancreatic, colorectal and breast cancers [<xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref>]. <italic toggle="yes">F. nucleatum</italic> has also been associated with preterm birth [<xref rid="cit0047" ref-type="bibr">47</xref>]; <italic toggle="yes">P. gingivalis</italic> has recently been shown to be involved in the development of atherosclerosis, rheumatoid arthritis, Alzheimer&#x02019;s disease [<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0048" ref-type="bibr">48</xref>,<xref rid="cit0049" ref-type="bibr">49</xref>] and <italic toggle="yes">T. denticola</italic> has been implicated in Alzheimer&#x02019;s disease amongst other systemic diseases and disorders [<xref rid="cit0050" ref-type="bibr">50</xref>]. Consequently, limiting the proliferation of these bacterial species in the oral cavity may also have significant human health benefits outside the oral cavity.</p></sec><sec disp-level="1" id="s0004"><title>Bacteriophages</title><p>Bacteriophage (from the Greek &#x02018;bacterium eater&#x02019;) are viruses that are obligate intracellular parasites of bacteria. They are the most diverse and numerous biological semiautonomous entities on the planet, estimated to number in excess of 10<sup>30</sup> individual virus particles [<xref rid="cit0051" ref-type="bibr">51</xref>]. Bacteriophages play as yet poorly defined roles in bacterial ecology, but some estimates describe a high turnover of bacteria by bacteriophages.</p></sec><sec disp-level="1" id="s0005"><title>Bacteriophage classification</title><p>While classification of bacteriophages by the International Committee on Taxonomy of Viruses (ICTV) is under revision due to expansion and diversity of characterised viruses [<xref rid="cit0052" ref-type="bibr">52</xref>], morphologically, bacteriophages exist as tailed, non-tailed and filamentous forms (<xref rid="t0001" ref-type="table">Table 1</xref>). Filamentous bacteriophages belong to the class <italic toggle="yes">Faserviricetes</italic> and order <italic toggle="yes">Tubulavirales</italic>, which is composed of three families, <italic toggle="yes">Inoviridae, Plectroviridae</italic> and <italic toggle="yes">Paulinoviridae</italic> [ICTV (accessed 31/01/2023]. Tailed bacteriophages now classified as <italic toggle="yes">Caudoviricetes</italic> are commonly isolated and characterised, and exist in three main morphotypes, (i) Siphovirus: characterised by an icosahedral capsid and a long and flexible tail (ii) Myovirus: characterised by an icosahedral capsid and a rigid but contractile tail, and (iii) Podovirus consisting of
an icosahedral capsid and short tail. Currently, a significant proportion of sequenced tailed bacteriophages remain unclassified at the family-level and a diverse group of non-tailed bacteriophages remain ungrouped into order or class [ICTV (accessed 31/01/2023)].<table-wrap position="float" id="t0001"><label>Table 1.</label><caption><p>Classification of bacteriophages.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="left"/></colgroup><thead><tr><th align="left">Nucleic acid type</th><th align="center">Class</th><th align="center">Morphology and bacteriophage families</th><th align="center">Illustration and electron micrograph</th></tr></thead><tbody><tr><td rowspan="3" align="left">Tailed (dsDNA)</td><td rowspan="3" align="left">Caudoviricetes</td><td align="left"><italic toggle="yes"><bold>Myoviruses</bold></italic>:<break/><italic toggle="yes">Ackermannviridae, Aggregaviridae, Assiduviridae, Chaseviridae, Herelleviridae, Hafunaviridae, Kyanoviridae, Molycolviridae, Soleiviridae, Halomagnusviridae, Peduoviridae, Pyrstoviridae, Soleiviridae, Vertoviridae, and Winoviridae</italic></td><td align="left"><inline-graphic xlink:href="ZJOM_A_2469890_ILG0001.jpg" id="ilg0001"/><break/>[<xref rid="cit0053" ref-type="bibr">53</xref>]</td></tr><tr><td align="left"><italic toggle="yes"><bold>Siphovirus</bold>: Anaerodiviridae, Casjensviridae, Demerecviridae, Drexlerviridae, Druskaviridae, Duneviridae, Haloferuviridae, Helgolandviridae, Forsetiviridae, Graaviviridae, Leisingerviridae, Madisaviridae, Mesyanzhinovviridae, Naomviridae, Orlajensenviridae, Vertoviridae, Suolaviridae, Saparoviridae, Straboviridae, Vilmaviridae, and Zierdtviridae</italic></td><td align="left"><inline-graphic xlink:href="ZJOM_A_2469890_ILG0002.jpg" id="ilg0002"/><break/>[<xref rid="cit0054" ref-type="bibr">54</xref>]</td></tr><tr><td align="left"><italic toggle="yes"><bold>Podovirus</bold>: Autographiviridae, Crevaviridae, Guelinviridae, Intestiviridae, Pachyviridae, Pervagoviridae, Rountreeviridae, Salasmaviridae, Schitoviridae, Steigviridae, Shortaselviridae, and Zobellviridae</italic></td><td align="left"><inline-graphic xlink:href="ZJOM_A_2469890_ILG0003.jpg" id="ilg0003"/><break/>[<xref rid="cit0055" ref-type="bibr">55</xref>]</td></tr><tr><td rowspan="3" align="left">Non-tailed (dsDNA)</td><td rowspan="2" align="left">Tectiliviricetes</td><td align="left"><bold>Icosahedral virions, ~57&#x02009;nm</bold><break/><italic toggle="yes">Corticoviridae</italic></td><td align="left">Spike proteins<inline-graphic xlink:href="ZJOM_A_2469890_ILG0004.jpg" id="ilg0004"/><break/>[<xref rid="cit0056" ref-type="bibr">56</xref>]</td></tr><tr><td align="left"><bold>Non-envelope with flexible spikes, ~66&#x02009;nm</bold><break/><italic toggle="yes">Tectiviridae</italic></td><td align="left">Flexible spike proteins<inline-graphic xlink:href="ZJOM_A_2469890_ILG0005.jpg" id="ilg0005"/><break/>[<xref rid="cit0057" ref-type="bibr">57</xref>]</td></tr><tr><td align="left"><italic toggle="yes">Not classified</italic></td><td align="left"><bold>Slightly pleomorphic, enveloped viruses, 50&#x02013;125&#x02009;nm</bold><italic toggle="yes">Plasmaviridae</italic></td><td align="left">Lipid membrane<inline-graphic xlink:href="ZJOM_A_2469890_ILG0006.jpg" id="ilg0006"/><break/>[<xref rid="cit0058" ref-type="bibr">58</xref>]</td></tr><tr><td rowspan="3" align="left">ssDNA</td><td align="left">Malgrandaviricetes</td><td align="left"><bold>Microvirus</bold><break/><italic toggle="yes">Microviridae</italic></td><td align="left">Mushroom shaped protrusions<inline-graphic xlink:href="ZJOM_A_2469890_ILG0007.jpg" id="ilg0007"/><break/>[<xref rid="cit0059" ref-type="bibr">59</xref>]</td></tr><tr><td rowspan="2" align="left">Faserviricetes</td><td align="left"><bold>Flexible filamentous virus,&#x02009;~&#x02009;7&#x02009;nm diameter</bold><break/><italic toggle="yes">Inoviridae</italic><break/><italic toggle="yes">Paulinoviridae</italic></td><td rowspan="2" align="left"><inline-graphic xlink:href="ZJOM_A_2469890_ILG0008.jpg" id="ilg0008"/><break/>[<xref rid="cit0059" ref-type="bibr">59</xref>]</td></tr><tr><td align="left"><bold>Non-enveloped rigid rods</bold><break/><italic toggle="yes">Plectroviridae</italic></td></tr><tr><td align="left">dsRNA</td><td align="left">Vidavericetes</td><td align="left"><bold>Enveloped spherical virus,&#x02009;~&#x02009;85&#x02009;nm diameter</bold><break/><italic toggle="yes">Cystoviridae</italic></td><td align="left">Surface protein<inline-graphic xlink:href="ZJOM_A_2469890_ILG0009.jpg" id="ilg0009"/><break/>[<xref rid="cit0059" ref-type="bibr">59</xref>]</td></tr><tr><td align="left">ssRNA</td><td align="left">Leviviricetes</td><td align="left"><bold>Non-enveloped spherical virus, ~26&#x02009;nm diameter</bold><break/><italic toggle="yes">Fiersviridae</italic></td><td align="left">Maturation protein<inline-graphic xlink:href="ZJOM_A_2469890_ILG0010.jpg" id="ilg0010"/><break/>[<xref rid="cit0059" ref-type="bibr">59</xref>]</td></tr></tbody></table></table-wrap></p><p>Bacteriophages exist as either double or single stranded DNA or RNA viruses. The majority of isolated and sequenced bacteriophage genomes contain double stranded (ds) DNA [<xref rid="cit0060" ref-type="bibr">60</xref>]. At approximately 4.4&#x02013;500 kb [<xref rid="cit0061" ref-type="bibr">61</xref>] in size, their genomes are small, in comparison to other microbes (bacterial genomesfor example, are in the range of 160 kb for microbacteria to 10 Mb for macrobacteria [<xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0063" ref-type="bibr">63</xref>]). This factor makes them very efficient replicating entities. The bacteriophage genome is composed of clusters of operons or cassettes, usually in the order of genes encoding proteins involved in lysogeny, DNA replication, regulation of transcription, DNA packaging and head assembly, tail, and lysis functions [<xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>].</p><p>There are two main bacteriophage lifestyles. Lytic bacteriophages do not integrate into the bacterial DNA and cause cell lysis following replication, releasing more copies of themselves in the process. In the lysogenic life cycle, prophages or temperate bacteriophages integrate their DNA into host chromosomal DNA and their genomes are replicated along with that of the host [<xref rid="cit0066" ref-type="bibr">66</xref>]. In their lysogenic form, these bacteriophages may enhance the persistence and virulence characteristics such as biofilm formation of the host bacteria [<xref rid="cit0067" ref-type="bibr">67</xref>]. Lytic bacteriophages may produce endolysins that digest the cell wall when exiting the host bacteria [<xref rid="cit0068" ref-type="bibr">68</xref>]. Certain temperate bacteriophages have been shown to undergo the lytic cycle when induced in the laboratory or spontaneously. For instance, bacteria containing prophages may be exposed to ultra-violet light or cytotoxic agents such as mitomycin C and these environmental insults induce the temperate bacteriophage to undergo the lytic cycle when host bacteria are exposed to potential DNA damage. This DNA damage may be unrepairable triggering cell SOS responses [<xref rid="cit0069" ref-type="bibr">69</xref>].</p></sec><sec disp-level="1" id="s0006"><title>Bacteriophage therapy</title><p>Bacteriophage therapy involves the targeted application of bacteriophage(s) that, upon encounter with specific pathogenic bacteria, infect and kill them. Their initial application for treatment of bacterial infections was independently described by Frederick Twort in 1915 and two years later by Felix d&#x02019;Herelle [<xref rid="cit0070" ref-type="bibr">70&#x02013;72</xref>]. Although their therapeutic use continued in Eastern Europe (Russian and Georgia) [<xref rid="cit0073" ref-type="bibr">73</xref>], interest in Western countries waned due to inconsistent and variable efficacy observed earlier on and the discovery of penicillin by Alexander Fleming in 1929 [<xref rid="cit0074" ref-type="bibr">74</xref>].
However, the emergence of the antimicrobial resistance pandemic [<xref rid="cit0075" ref-type="bibr">75</xref>] has renewed the interest of therapeutic bacteriophages in many parts of the world including Australia, Europe, America and Africa where bacteriophage banks [<xref rid="cit0076" ref-type="bibr">76</xref>] and clinical trials are being established [<xref rid="cit0077" ref-type="bibr">77</xref>].</p><p>Bacteriophage(s) lyse the bacteria, releasing virion progeny that continue the cycle. Bacteriophages are unique among antibacterial agents in their ability to increase their numbers when in the presence of bacterial targets. Of similar importance, bacteriophages only minimally impact non-target bacteria or body tissues [<xref rid="cit0078" ref-type="bibr">78</xref>]. Displaying a narrow spectrum of activity can be a useful property for an antibacterial [<xref rid="cit0079" ref-type="bibr">79</xref>], and this feature makes bacteriophages an attractive option in instances where precision therapy is required. For a detailed history of the use of bacteriophage therapy to treat human infections beginning shortly after the discovery of bacteriophage and extending to recent times see Abedon <italic toggle="yes">et al.</italic> [<xref rid="cit0078" ref-type="bibr">78</xref>]. A recent meta-analysis of early clinical trials of bacteriophage therapy conducted in the first half of the 20<sup>th</sup> century using a random effects model has demonstrated efficacy in the treatment of a wide variety of bacterial infections [<xref rid="cit0080" ref-type="bibr">80</xref>]. A recent review of bacteriophage clinical trials has indicated that while efficacy has not been reported in all clinical trials, all modern trials thus far have shown bacteriophage therapy to be safe [<xref rid="cit0081" ref-type="bibr">81</xref>].</p></sec><sec disp-level="1" id="s0007"><title>Bacteriophage isolation, choice and purification</title><p>Bacteriophages have co-evolved with bacteria and can be readily isolated from their bacterial host&#x02019;s habitats [<xref rid="cit0082" ref-type="bibr">82</xref>]. Lytic bacteriophages may be filtered from natural samples and sequenced as a purified bacteriophage population or as phageome through metagenomics. Lytic bacteriophages are preferred for use as anti-bacterial agents. It is therefore important that therapeutic bacteriophages do not undergo a lysogenic lifecycle or possess genes encoding toxins, antibiotic resistance or others that may enhance the pathogenicity of the target or commensal bacteria [<xref rid="cit0083" ref-type="bibr">83</xref>]. However, as lytic bacteriophages may not always be isolated [<xref rid="cit0084" ref-type="bibr">84</xref>], the temperate bacteriophages in the genomes of bacteria [<xref rid="cit0085" ref-type="bibr">85</xref>] may provide an option for therapy. These prophages may possess lysin genes, and the subsequent proteins may be purified and utilised as antimicrobials [<xref rid="cit0086" ref-type="bibr">86</xref>]. In clinical applications, preparations of bacteriophages and/or lysins need to be rid of contaminants such as endotoxins derived from their host bacteria [<xref rid="cit0087" ref-type="bibr">87</xref>].</p></sec><sec disp-level="1" id="s0008"><title>Bacteriophages for treatment of biofilm-forming bacteria</title><p>The vast majority of bacteria exist as components of polymicrobial biofilms with complex interactions and ecologies, especially in the human oral cavity. High levels of bacteriophage release in biofilms have been demonstrated and the resulting lysis of cells may provide nutrients allowing the persistence and proliferation of neighbouring cells as well as remodelling the structure of the biofilm [<xref rid="cit0088" ref-type="bibr">88</xref>,<xref rid="cit0089" ref-type="bibr">89</xref>].</p><p>Bacteriophages carry specific polysaccharide depolymerases that can degrade capsular polysaccharides, exopolysaccharides or lipopolysaccharide aiding viral penetration of complex bacterial biofilms and bacterial capsules [<xref rid="cit0090" ref-type="bibr">90</xref>]. Bacteriophages have been shown to have the capacity to diffuse through mono- and multi-species biofilms [<xref rid="cit0091" ref-type="bibr">91</xref>], possibly through the penetration of the extracellular polymeric matrix known to house water and nutrient channels and poles [<xref rid="cit0092" ref-type="bibr">92</xref>]. Kabwe <italic toggle="yes">et al.</italic> [<xref rid="cit0093" ref-type="bibr">93</xref>] demonstrated the efficacy of bacteriophage application to <italic toggle="yes">F. nucleatum</italic> monospecies biofilms. Apart from <italic toggle="yes">in-vitro</italic> and <italic toggle="yes">ex-vivo</italic> treatments in a human root canal model targeting <italic toggle="yes">Enterococcus faecalis</italic> [<xref rid="cit0094" ref-type="bibr">94</xref>], bacteriophages have not been applied to treat oral disease. However, bacteriophages have successfully been used to treat other biofilm infections in humans, although exact compositions of bacteriophage preparations have not been completely reported. In wound infections, 13 studies reviewed by Duplesis and Biswas [<xref rid="cit0095" ref-type="bibr">95</xref>] (342 patients in total) reported efficacy ranging from 70% to 100%. Genevi&#x000e8;re <italic toggle="yes">et al.</italic> [<xref rid="cit0096" ref-type="bibr">96</xref>] reviewed 20 studies comprising 51 patients with a bacteriophage success rate of 71% in prosthetic joint and bone infections, while more recently, four patients have been successfully treated
for chronic relapsing cardiovascular implant infections, one with a polymicrobial infection including MDR <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="cit0097" ref-type="bibr">97</xref>]. The efficacy and safety of a bacteriophage cocktail treatment for antibiotic resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>-associated chronic otitis was determined in a controlled double-blind Phase I/II clinical trial [<xref rid="cit0098" ref-type="bibr">98</xref>]. A phage cocktail containing six bacteriophages was applied directly into the ear of 12 patients whilst a control group of 12 patients received a placebo. A significant improvement in clinical indicators of disease, a decrease in <italic toggle="yes">P. aeruginosa</italic> counts after treatment, and no adverse events, were reported.</p></sec><sec disp-level="1" id="s0009"><title>Engineered bacteriophages and bacteriophage-based products</title><p>In addition to &#x02018;native&#x02019; bacteriophage, engineered bacteriophage and their products offer opportunities for the development of novel therapeutic approaches. Well-characterised bacteriophages have been used for molecular biology applications due to their highly manipulable genomes [<xref rid="cit0099" ref-type="bibr">99</xref>]. However, bacteriophage engineering has also shown potential to assist in treatment of disease. For instance, prophage manipulation into lytic bacteriophage forms has been applied for treatment of disseminated drug-resistant <italic toggle="yes">Mycobacterium abscessus</italic> [<xref rid="cit0100" ref-type="bibr">100</xref>]. In other studies, bacteriophages have been engineered to modify their tail proteins, with which they recognise their host, to i) target emerging bacteriophage resistant mutants [<xref rid="cit0101" ref-type="bibr">101</xref>], ii) produce polyvalent bacteriophages that target different bacterial hosts [<xref rid="cit0102" ref-type="bibr">102</xref>,<xref rid="cit0103" ref-type="bibr">103</xref>] and iii) carry broad-spectrum antimicrobial peptides [<xref rid="cit0104" ref-type="bibr">104</xref>] for purposes of antimicrobial therapy or bacterial detection.</p><p>Upon attachment, bacteriophages may release enzymes known as ectolysins to facilitate the injection of their DNA into the bacteria [<xref rid="cit0105" ref-type="bibr">105</xref>]. During infection, these bacteriophages also express endolysins that target and lyse the bacterial cell wall peptidoglycan to release bacteriophages from inside the bacteria [<xref rid="cit0106" ref-type="bibr">106</xref>]. Although lytic bacteriophages are preferred as antimicrobials, they may not always be easily isolated [<xref rid="cit0084" ref-type="bibr">84</xref>]. Yet the genomes of many bacteria contain lysogenic prophage genomes [<xref rid="cit0085" ref-type="bibr">85</xref>]. These prophages may provide a library of proteins including lysins that could be repurposed as antimicrobials, potentially targeting the dysbiotic molecular pathways seen in chronic diseases [<xref rid="cit0086" ref-type="bibr">86</xref>]. Indeed, prophages have been described for three major periodontal pathobionts: <italic toggle="yes">F. nucleatum</italic> [<xref rid="cit0107" ref-type="bibr">107</xref>], <italic toggle="yes">P. gingivalis</italic> [<xref rid="cit0108" ref-type="bibr">108</xref>] and <italic toggle="yes">T. denticola</italic> [<xref rid="cit0067" ref-type="bibr">67</xref>].</p><p>Engineered bacteriophage can also be used as delivery vehicles for exogenous molecules using a process known as bacteriophage display. In this process peptides and/or proteins are expressed on the capsid of a bacteriophage, that is used to delivered the payload to a specific site [<xref rid="cit0099" ref-type="bibr">99</xref>]. This can be achieved through fusion of desired protein genes to the coat protein gene of the bacteriophage [<xref rid="cit0109" ref-type="bibr">109</xref>]. The displayed protein may be a peptide acting as an agonist or antagonist for receptor&#x02013;ligand interaction or as vaccine carriers for known antigens [<xref rid="cit0110" ref-type="bibr">110</xref>]. Bacteriophage display has also been used to carry antibodies used for treatment of autoimmunity [<xref rid="cit0111" ref-type="bibr">111</xref>], a snake bite venom [<xref rid="cit0112" ref-type="bibr">112</xref>], viral infection [<xref rid="cit0113" ref-type="bibr">113</xref>] and allergic reactions [<xref rid="cit0114" ref-type="bibr">114</xref>].</p></sec><sec disp-level="1" id="s0010"><title>Human oral phageome</title><p>The contribution of bacteriophages to the composition and function of the human microbiome has been largely overlooked until recently. A detailed exploration of the human oral phageome is beyond the scope of this review and is covered in an excellent recent publication by Szafra&#x00144;ski <italic toggle="yes">et al.</italic> [<xref rid="cit0115" ref-type="bibr">115</xref>]. Carr <italic toggle="yes">et al.</italic> [<xref rid="cit0116" ref-type="bibr">116</xref>] characterised the phageomes of 633&#x000a0;human oral sites using nucleic acid sequencing approaches. The host specificity of the bacteriophage can be inferred from the host genome sequence at the site where the virus integrates into the genome and by fragments of host DNA that are acquired by the bacteriophage and transferred between bacterial cells. The greatest bacteriophage diversity was found on the tongue and in plaque. Notably, 37 unique circular jumbo bacteriophage genomes were identified in oral sites, particularly on the dorsum of the tongue. Most oral metagenomes contained a high abundance of <italic toggle="yes">Caudoviricetes</italic>. Guo <italic toggle="yes">et al.</italic> [<xref rid="cit0117" ref-type="bibr">117</xref>] recently reviewed the roles of oral bacteriophages in a range of oral diseases and concluded that given the number of characterised bacteriophages specific for <italic toggle="yes">E.s faecalis</italic> there was significant potential for bacteriophage therapy development targetting endodontic infections associated with this bacterium. A recent systematic review encompassing 14 individual studies found that recent studies were highly heterogenous and tended to focus on the whole oral phageome. This led to difficulties in synthesizing and comparing the data, but overall indicated that there were associations between oral bacteriophages specific for <italic toggle="yes">Streptococcus</italic>, <italic toggle="yes">Actinomyces</italic>, <italic toggle="yes">Haemophilus</italic> and <italic toggle="yes">Veillonella</italic> and the oral diseases chronic periodontitis and caries [<xref rid="cit0118" ref-type="bibr">118</xref>].</p></sec><sec disp-level="1" id="s0011"><title>Known bacteriophages for periodontal pathobionts</title><p>A recent review of the human oral phageome [<xref rid="cit0115" ref-type="bibr">115</xref>] used the Integrated Microbial Genome/Virus (IMG/VR) database to predict bacteriophages specific for oral bacterial species. The 4th version of the IMG/VR database catalogues&#x02009;&#x0003e;15 million uncultivated viral genomes (UViGs) including both DNA and RNA viruses, identified as viral contigs or integrated
proviruses in genomes, metagenomes, or metatranscriptomes, all systematically annotated and available through the IMG/VR user interface (<ext-link xlink:href="https://img.jgi.doe.gov/vr/" ext-link-type="uri">https://img.jgi.doe.gov/vr/</ext-link>) [<xref rid="cit0119" ref-type="bibr">119</xref>]. Despite the prediction of these bacteriophage genomes in the oral phageome, reports of isolation of bacteriophages for oral pathobionts are rare. These bacteria have been shown to not thrive outside their natural habitat. This is in contrast to <italic toggle="yes">Enterobacteriaceae</italic> such as <italic toggle="yes">Klebsiella</italic> [<xref rid="cit0120" ref-type="bibr">120</xref>], and as such, bacteriophages against this group are readily isolated from external environments such as wastewater sources [<xref rid="cit0082" ref-type="bibr">82</xref>]. Further, oral pathobionts such as <italic toggle="yes">Porphyromonas gingivalis</italic> [<xref rid="cit0121" ref-type="bibr">121</xref>] and <italic toggle="yes">Streptococcu</italic>s <italic toggle="yes">mutans</italic> [<xref rid="cit0122" ref-type="bibr">122</xref>] have been shown to possess an extensive range of genes coding for CRISPR (clustered regularly interspaced short palindromic repeats) and CRISPR spacer sequences. It is also important to note that occasional differences between the genomes of predicted prophages and those that can be induced in the laboratory occur and may reflect the fact that some prophages may not be easily induced using current methods. For instance, some of the prophage genomic sequences previously identified in the genome of <italic toggle="yes">Pseudomonas aeruginosa</italic> were not detected after induction of prophages with norfloxacin or boiling bacterial suspensions [<xref rid="cit0123" ref-type="bibr">123</xref>]. This suggests that there is room for refinement of methods for characterising lysogeny, and improvement of both in-silico and experimental analyses, to better understand prophage diversity and activity [<xref rid="cit0085" ref-type="bibr">85</xref>].</p><p>Below are key bacteria taxa, mainly at a species level, that are associated with the progression of periodontitis based on the recent comprehensive review by Balan <italic toggle="yes">et al.</italic> [<xref rid="cit0022" ref-type="bibr">22</xref>] and the microbiomic analysis of nonresponding sites after mechanical debridement ([<xref rid="cit0023" ref-type="bibr">23</xref>]; <xref rid="f0003" ref-type="fig">Figure 3</xref>). Currently, available information regarding specific bacteriophages for these bacteria is presented.</p><sec disp-level="2" id="s0011-s2001"><title>Bacteroidetes</title><p>Most currently predicted or isolated bacteriophages of the Bacteroidetes infect commensal species with only a small number known to infect species associated with disease progression [<xref rid="cit0115" ref-type="bibr">115</xref>].</p><p><italic toggle="yes">Porphyromonas gingivalis</italic> - to date there are no reports of the isolation of bacteriophages lytic for this species, or closely related species, such as <italic toggle="yes">Porphyromonas endodontalis</italic>, that have also been strongly associated with disease progression. Matrishin et al. [<xref rid="cit0124" ref-type="bibr">124</xref>] using a bioinformatic <italic toggle="yes">in silico</italic> approach focused on temperate phage discovery found taxonomically diverse prophages are common in <italic toggle="yes">P. gingivalis</italic> being found in approximately a third of the examined genomes. This may explain the abundant prevalence of CRISPR-Cas systems in this species [<xref rid="cit0121" ref-type="bibr">121</xref>]. CRISPR-Cas systems are known to identify and target specific foreign DNA sequences, acting to limit bacteriophage infection. Fragments of bacteriophage DNA become incorporated into the bacterial genome on CRISPR memory arrays, and RNA probes transcribed from these arrays can identify the complementary invading bacteriophage DNA and guide antiphage bacterial nucleases.</p><p><italic toggle="yes">Tannerella forsythia</italic> is predicted to host at least four distinct bacteriophages by the IMG/VR database [<xref rid="cit0115" ref-type="bibr">115</xref>], to date none of these have been isolated.</p><p><italic toggle="yes">Bacteroidales</italic> [G-2] bacterium HMT 274 - no bacteriophages have been reported to be associated with this taxon although 23 are predicted to infect <italic toggle="yes">Bacteroidales</italic> [F-2] [G-2] HMT-272 [<xref rid="cit0115" ref-type="bibr">115</xref>]. The imprecise nature of the taxonomy of uncultivated oral bacterial species may confound the prediction of bacteriophage specificity based purely on genomic sequence data and it is possible that some of the 23 predicted bacteriophages of <italic toggle="yes">Bacteroidales</italic> [F-2] [G-2] HMT-272 May infect <italic toggle="yes">Bacteroidales</italic> [G-2] bacterium HMT 274.</p><p><italic toggle="yes">Prevotella intermedia</italic> &#x02212; 19 bacteriophages have been found to be associated with <italic toggle="yes">P. intermedia/Prevotella nigrescens</italic> based on sequence data [<xref rid="cit0115" ref-type="bibr">115</xref>] although there are no reports of active bacteriophages to date.</p></sec><sec disp-level="2" id="s0011-s2002"><title>Spirochaetes</title><p>The genus <italic toggle="yes">Treponema</italic> contains a relatively large number of species that are associated with periodontitis and none that are associated with health. A number of oral treponemes have been closely associated with disease, the best studied of which is <italic toggle="yes">Treponema denticola</italic>, followed by <italic toggle="yes">Treponema socranskii. Treponema lecithinolyticum</italic>, <italic toggle="yes">Treponema maltophilum</italic> and <italic toggle="yes">Treponema</italic> sp. HMT 237 (<italic toggle="yes">medium</italic>) [<xref rid="cit0125" ref-type="bibr">125</xref>].</p><p>To date a single bacteriophage &#x003a8;td1&#x000a0;has been isolated and characterised from a single oral spirochaete, <italic toggle="yes">T. denticola</italic> [<xref rid="cit0067" ref-type="bibr">67</xref>]. The bacteriophage was initially discovered as a prophage in the bacterial genome and subsequently shown to be inducible and lytic. Similar to previously discovered spirochaete bacteriophages &#x003a8;td1 is a tailed, double-stranded DNA, temperate bacteriophage that has been observed to have a contractile tail, indicating a Myovirus morphotype [<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0126" ref-type="bibr">126</xref>]. The IMG/VR database includes two oral bacteriophages that are predicted to infect <italic toggle="yes">T. socranskii</italic> [<xref rid="cit0115" ref-type="bibr">115</xref>].</p></sec><sec disp-level="2" id="s0011-s2003"><title>Fusobacteria</title><p>The species <italic toggle="yes">Fusobacterium nucleatum</italic> consists of several subspecies most of which have been associated with disease. The four best characterised subspecies are <italic toggle="yes">F. nucleatum nucleatum, F. nucleatum animalis,
F. nucleatum polymorphum</italic> and <italic toggle="yes">F. nucleatum vincentii</italic>. None of these subspecies are differentiated in 16s RNA gene microbiomic studies, possibly limiting our understanding of their specific roles in disease and health.</p><p>A total of 147 bacteriophages, including 26 jumbo bacteriophages, are linked to <italic toggle="yes">Fusobacterium</italic> spp. through sequence analysis although the species are not well identified [<xref rid="cit0115" ref-type="bibr">115</xref>]. Kabwe <italic toggle="yes">et al.</italic> [<xref rid="cit0093" ref-type="bibr">93</xref>] isolated and characterised FNU1 from <italic toggle="yes">F. nucleatum polymorphum</italic>. FNU1 is a large <italic toggle="yes">Siphoviridae</italic> virus with a genome of 130,914 bp, a capsid diameter of 88&#x02009;nm and a tail of ~310&#x02009;nm in length that was shown to disrupt <italic toggle="yes">F. nucleatum</italic> biofilms (<xref rid="f0004" ref-type="fig">Figure 4</xref>). FNU1&#x000a0;has been proposed as a potential treatment for <italic toggle="yes">F. nucleatum</italic>-mediated diseases and conditions including colorectal cancer [<xref rid="cit0127" ref-type="bibr">127</xref>]. More recently, Wang <italic toggle="yes">et al.</italic> [<xref rid="cit0128" ref-type="bibr">128</xref>] isolated five <italic toggle="yes">F. nucleatum</italic> myoviruses from saliva of healthy individuals (JD-Fnp1, JD-Fnp2, JD-Fnp3, JD-Fnp4) and faecal samples from a colorectal cancer patient (JD-Fnp5). Cochrane et al. [<xref rid="cit0107" ref-type="bibr">107</xref>] isolated two prophages from <italic toggle="yes">F. nucleatum animalis</italic> and designated them &#x00278;Funu1 and &#x00278;Funu2. &#x00278;Funu2 was not able to bind to <italic toggle="yes">F. nucleatum</italic> and induce active lysis. Using bioinformatics approaches, they predicted the presence of up to 39 bacteriophages in the genomes of 16 <italic toggle="yes">F. nucleatum</italic> strains although the majority of these were incomplete or questionable, indicating possible limitations of prediction software.
<fig position="float" id="f0004" fig-type="figure"><label>Figure 4.</label><caption><p>Confocal images of SYBR&#x000ae; gold and propidium iodide staining following FNU1 bacteriophage treated (a) and untreated (b) <italic toggle="yes">Fusobacterium nucleatum</italic> biofilm. Reprinted with permission from Kabwe et al. [<xref rid="cit0060" ref-type="bibr">60</xref>].</p></caption><alternatives><graphic xlink:href="ZJOM_A_2469890_F0004_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="ZJOM_A_2469890_F0004_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p></sec><sec disp-level="2" id="s0011-s2004"><title>Firmicutes</title><p><italic toggle="yes">Filifactor alocis</italic> has no known bacteriophage, although this may be due to minimal experimental efforts in discovery of these.</p></sec><sec disp-level="2" id="s0011-s2005"><title>Synergistes</title><p>The IMG/VR database includes the draft genome sequences of two oral bacteriophages, one of which is a jumbo bacteriophage, that are predicted to infect <italic toggle="yes">Fretibacterium fastidiosum</italic> [<xref rid="cit0119" ref-type="bibr">119</xref>].</p></sec><sec disp-level="2" id="s0011-s2006"><title>Proteobacteria</title><p><italic toggle="yes">Desulfobulbus</italic> sp. HMT 041&#x000a0;has no known or predicted bacteriophage to date.</p></sec></sec><sec disp-level="1" id="s0012"><title>Potential for bacteriophages as adjunctive treatment in periodontitis</title><p>A curated mixture of bacteriophages may have efficacy in the treatment of periodontal pockets that do not respond to conventional mechanical debridement. These could potentially be applied in a slow release form to all treated pockets at the time of treatment. Mechanical debridement will substantially disrupt the subgingival bacterial biofilms enabling a high level of penetration for the bacteriophage. Although lack of understanding of bacteriophage pharmacokinetics and pharmacodynamics has been described as a major hurdle to clinical translation [<xref rid="cit0129" ref-type="bibr">129</xref>], bacteriophages have shown favourable outcomes when used as adjunct to other existing therapies in a range of diseases. When used in conjunction with antibiotics, bacteriophage T4&#x000a0;has been shown to have enhanced burst size and to reduce the effective minimum biofilm eradication concentration of cefotaxime against <italic toggle="yes">Escherichia coli</italic> [<xref rid="cit0130" ref-type="bibr">130</xref>]. Further, bacteriophage/antibiotic synergy has been shown to extend susceptibility in previously antibiotic resistant pathogenic <italic toggle="yes">E. coli</italic> harbouring chloramphenicol acetyltransferase or beta-lactamase enzymes [<xref rid="cit0131" ref-type="bibr">131</xref>] and bacteriophage resistance [<xref rid="cit0132" ref-type="bibr">132</xref>]. Efficacy and synergy of bacteriophage and antibiotic therapy has also been shown in longer term clinical applications. After 3&#x02009;years of continuous ceftazidime therapy, Chan <italic toggle="yes">et al.</italic> [<xref rid="cit0133" ref-type="bibr">133</xref>] were able to wean a 76-year-old patient with a <italic toggle="yes">P. aeruginosa</italic> mediastinal and aortic graft infection off the antibiotics by administering bacteriophage OMKO1 together with ceftazidime. Similarly,
Ferry and colleagues, after treatment failure with prolonged systemic antibiotic therapy, used a cocktail of three bacteriophages in addition to surgery and antibiotic therapy to manage three elderly patients with <italic toggle="yes">S. aureus</italic> infected prosthetic knee infections [<xref rid="cit0134" ref-type="bibr">134</xref>]. Although highly complex and capable of avoiding the development of bacterial resistance mechanisms through evolutionary processes there still remains the possibility that overuse or incorrect use of bacteriophages will result in the resistance being developed [<xref rid="cit0008" ref-type="bibr">8</xref>]. Some bacteria such as <italic toggle="yes">Listeria monocytogenes</italic>, <italic toggle="yes">E. faecalis</italic> and <italic toggle="yes">Acinetobacter baumannii</italic> are known to convert to capsule-deficient forms in order to develop bacteriophage resistance [<xref rid="cit0135" ref-type="bibr">135</xref>,<xref rid="cit0136" ref-type="bibr">136</xref>]. This however, renders target bacteria susceptible to antibiotics [<xref rid="cit0135" ref-type="bibr">135</xref>] and less virulent [<xref rid="cit0137" ref-type="bibr">137</xref>]. Further, while bacteriophage and antibiotic synergy has been observed in many applications, some studies have shown minimal or antagonistic effects. For instance, using the bacteria <italic toggle="yes">P. aeruginosa</italic>, no synergy was observed between the bacteriophage KPP25 and any antibiotic tested [<xref rid="cit0138" ref-type="bibr">138</xref>]. Antagonistic effects with bacteriophages and antibiotics have also been observed in <italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">Bacillus cereus</italic> treatments [<xref rid="cit0139" ref-type="bibr">139</xref>]. It is unclear why observed interactions between bacteriophages and antibiotics vary.</p></sec><sec disp-level="1" id="s0013"><title>Potential application, delivery and regulation of bacteriophage therapy in periodontal disease</title><p>As shown by Byrne et al. [<xref rid="cit0023" ref-type="bibr">23</xref>] the microbiome profile of the periodontal sites is an important prognostic marker. The population of non-responders or relapsing patients would be the target group for trialling the effectiveness of bacteriophages in periodontitis. In this case, a cocktail of bacteriophages specifically targeting identified bacterial pathobionts would be ideal. We have previously shown that bacteriophages can be formulated into a range of dosage forms, including (tooth) pastes and lozenges [<xref rid="cit0140" ref-type="bibr">140</xref>], however to be effective in the treatment of periodontitis a specific subgingival application is required. For subgingival application, bacteriophage suspensions could be directly applied during the debridement process, and subsequently. Dental floss impregnated with lyophilised bacteriophages could allow activation of the viruses in the moist subgingival environment [<xref rid="cit0141" ref-type="bibr">141</xref>]. This diverse range of therapeutic delivery forms could assist in limiting local inflammation and damage induced by the oral pathobionts, as well as their spread to distant sites where they may contribute to other serious chronic diseases.</p></sec><sec disp-level="1" id="s0014"><title>Potential risks for the development of bacteriophage therapy</title><p>A potential issue when considering bacteriophage therapy is the risk of host bacteria developing resistance and reduced susceptibility to lysis by the virus. Bacteria may mutate and evolve to overcome the threat from the lytic bacteriophage. They also possess sophisticated innate defence systems, including restriction-modification and CRISPR-Cas systems [<xref rid="cit0142" ref-type="bibr">142</xref>]. Therefore, bacterial defence systems, along with mechanisms for bacteriophage to counter them, play a role in bacteriophage resistance. Approaches for overcoming bacteriophage resistance include allowing bacteria and virus to co-evolve, the use of genetic engineering, co-treatment with antibiotics, and targeting biofilm-forming pathways such as quorum sensing [<xref rid="cit0143" ref-type="bibr">143</xref>].</p><p>Some bacteriophages have been shown to induce an inflammatory immune response when used in therapy, accompanied by bacteriophage-specific antibodies [<xref rid="cit0144" ref-type="bibr">144</xref>]. In the oral cavity, secretory immunoglobulin A (sIgA) is the primary immunoglobulin [<xref rid="cit0145" ref-type="bibr">145</xref>], and bacteriophage therapy has been shown to induce treatment limiting humoral immunity via sIgA in the gut [<xref rid="cit0144" ref-type="bibr">144</xref>]. As such, it may be prudent for bacteriophages used in periodontitis therapy to be tested against the patient&#x02019;s sera before administration. In immune-compromised patients, bacteriophages have been shown to be safe [<xref rid="cit0146" ref-type="bibr">146</xref>].</p><p>The narrow host range/spectrum of bacteriophages provides both an advantage and a disadvantage. In acute critical care, this may be a disadvantage as there will be the requirement for screening of bacteriophages for their specificity. In such circumstances, broad spectrum antibiotics may be considered. However, in treatment of periodontitis, the precision and specificity of bacteriophages provides a valuable weapon for targeting pathobionts without affecting the healthy microbiota in the process.</p><p>Antibiotic resistance genes may be transferred between bacteria through horizontal gene transfer. It is possible that with extensive bacteriophage therapy, resistance to bacteriophages may be similarly transferred. In the past decade or so, many previously unknown prokaryotic defence systems have been characterised [<xref rid="cit0142" ref-type="bibr">142</xref>]. However, because bacteriophages are very specific to their hosts, it has been argued that it is unlikely that increased exposure will result in widespread bacteriophage resistance [<xref rid="cit0147" ref-type="bibr">147</xref>].</p><p>The success of bacteriophage therapy depends on its safety and efficacy. Bacteriophages are cultured on bacterial hosts and this process leads to production of bacterial debris known as endotoxins. As with other therapeutics, bacteriophages need to be tested for safety. In parenteral administration, less than 5 endotoxin units/kg body weight is permitted, and reproducibility is required to meet Good Manufacturing Practices [<xref rid="cit0148" ref-type="bibr">148</xref>]. Because of their delicate nature, crude bacteriophage manufacturing processes may lead to structural damage and loss of efficacy [<xref rid="cit0149" ref-type="bibr">149</xref>]. Bacteriophages for the treatment of periodontitis will need to meet regulatory hurdles associated with clinical trials prior to approval [<xref rid="cit0150" ref-type="bibr">150</xref>]. Currently, there are no
approved regulations for bacteriophage treatment. However, with increasing evidence of their therapeutic capacity, many governing bodies such as Australian Therapeutic Goods Administration, European Medicines Agency and the United States Food and Drug Administration are becoming more amenable to approving the compassionate and magistral use of bacteriophages in therapy [<xref rid="cit0151" ref-type="bibr">151</xref>,<xref rid="cit0152" ref-type="bibr">152</xref>]. Regulation following a framework set out for similar therapeutic goods [<xref rid="cit0153" ref-type="bibr">153</xref>,<xref rid="cit0154" ref-type="bibr">154</xref>] e.g. attenuated virus vaccines, may facilitate the use of bacteriophages in patients.</p></sec><sec disp-level="1" id="s0015"><title>Conclusions</title><p>In the long-term bacteriophage therapy offers the potential to be a safe, specific and efficacious adjunctive treatment to current gold standard periodontal treatment to stop the reassembly of pathogenic subgingival plaque biofilm communities and subsequent failure of treatment. There are a number of barriers to the implementation of bacteriophage therapy to a chronic disease caused by a dysbiosis of endogenous bacterial communities. To realize the potential for bacteriophage therapy there must initially be a greater research effort focussed on discovery, identification, characterization and isolation of bacteriophage that target key oral bacteria essential for pathogenic dysbiotic community development. This will require the determination of the specificity of isolated and purified bacteriophage coupled with a deeper understanding of which oral bacteria are crucial for the development of the dysbiotic subgingival bacterial communities that drive disease. It is highly likely that multiple bacteriophages will need to be formulated into cocktails that may be dependent on the bacterial species present in individuals. This is likely to require the development of bacteriophage biobanks and potentially incorporation of personalized medicine approaches. In addition, effort will need to be expended to develop more applicable models of this polymicrobial chronic disease.</p></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge the Cass (Contributing to Australian Scholarship and Science) Foundation for their support of our research. MK was supported by a La Trobe University Full Fee Research Scholarship and the Research Training Program Scholarship, and is currently the recipient of a La Trobe University ABC internal Investment Scheme Award.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0016"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec disp-level="1" id="s0017"><title>Abbreviations</title><p>
<def-list><def-item><term>CAL</term><def><p>clinical attachment loss</p></def></def-item><def-item><term>CRISPR</term><def><p>clustered regularly interspaced short palindromic repeats</p></def></def-item><def-item><term>dsDNA</term><def><p>double stranded DNA</p></def></def-item><def-item><term>IMG/VR</term><def><p>Integrated Microbial Genome/Virus database</p></def></def-item><def-item><term>ICTV</term><def><p>International Committee on Taxonomy of Viruses</p></def></def-item><def-item><term>UViGs</term><def><p>uncultivated viral genomes</p></def></def-item></def-list></p></sec><sec disp-level="1" id="s0018"><title>Author contributions</title><p>M.K., J.T., I.D., and S.D. wrote the manuscript. S.D. conceived the concept of this review. All authors discussed and commented on the manuscript.</p></sec><sec disp-level="1" id="s0019"><title>Data sharing</title><p>Data sharing is not applicable to this article as no new data were created or analyzed in this study.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kassebaum</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bernab&#x000e9;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Dahiya</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Global burden of severe periodontitis in 1990&#x02013;2010: a systematic review and meta-regression</article-title>. <source>J Dent Res</source>. <year>2014</year>;<volume>93</volume>(<issue>11</issue>):<fpage>1045</fpage>&#x02013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0022034514552491</pub-id><pub-id pub-id-type="pmid">25261053</pub-id>
</mixed-citation></ref><ref id="cit0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eke</surname>
<given-names>PI</given-names></string-name>, <string-name><surname>Dye</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Prevalence of periodontitis in adults in the United States: 2009 and 2010</article-title>. <source>J Dent Res</source>. <year>2012</year>;<volume>91</volume>(<issue>10</issue>):<fpage>914</fpage>&#x02013;<lpage>920</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0022034512457373</pub-id><pub-id pub-id-type="pmid">22935673</pub-id>
</mixed-citation></ref><ref id="cit0003"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Billings</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Holtfreter</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Papapanou</surname>
<given-names>PN</given-names></string-name>, et al</person-group>. <article-title>Age&#x02010;dependent distribution of periodontitis in two countries: findings from NHANES 2009 to 2014 and SHIP&#x02010;TREND 2008 to 2012</article-title>. <source>J Clin Periodontol</source>. <year>2018</year>;<volume>45</volume>(<issue>S20</issue>):<fpage>S130</fpage>&#x02013;<lpage>S148</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcpe.12944</pub-id><pub-id pub-id-type="pmid">29926501</pub-id>
</mixed-citation></ref><ref id="cit0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Papapanou</surname>
<given-names>PN</given-names></string-name>, <string-name><surname>Sanz</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Buduneli</surname>
<given-names>N</given-names></string-name>, et al</person-group>. <article-title>Periodontitis: consensus report of workgroup 2 of the 2017 World workshop on theclassification of periodontal and peri&#x02010;implant diseases and conditions</article-title>. <source>J Periodontol</source>. <year>2018</year>;<volume>89 Suppl 1</volume>:<fpage>S173</fpage>&#x02013;<lpage>S182</lpage>. doi: <pub-id pub-id-type="doi">10.1002/JPER.17-0721</pub-id><pub-id pub-id-type="pmid">29926951</pub-id>
</mixed-citation></ref><ref id="cit0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanz</surname>
<given-names>M</given-names></string-name><string-name><surname>Herrera</surname>
<given-names>D</given-names></string-name><string-name><surname>Kebschull</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Treatment of stage I&#x02013;III periodontitis&#x02014;the EFP S3 level clinical practice guideline</article-title>. <source>J Clin Periodontol</source>. <year>2020</year>;<volume>47</volume>(<issue>S22</issue>):<fpage>4</fpage>&#x02013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcpe.13290</pub-id><pub-id pub-id-type="pmid">32383274</pub-id>
</mixed-citation></ref><ref id="cit0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durham</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fraser</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>McCracken</surname>
<given-names>GI</given-names></string-name>, et al</person-group>. <article-title>Impact of periodontitis on oral health-related quality of life</article-title>. <source>J Dent</source>. <year>2013</year>;<volume>41</volume>(<issue>4</issue>):<fpage>370</fpage>&#x02013;<lpage>376</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jdent.2013.01.008</pub-id><pub-id pub-id-type="pmid">23357646</pub-id>
</mixed-citation></ref><ref id="cit0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Linden</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Lyons</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scannapieco</surname>
<given-names>FA.</given-names></string-name></person-group>
<article-title>Periodontal systemic associations: review of the evidence</article-title>. <source>J Clin Periodontol</source>. <year>2013</year>;<volume>40</volume>(<issue>s14</issue>):<fpage>S8</fpage>&#x02013;<lpage>S19</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcpe.12064</pub-id><pub-id pub-id-type="pmid">23627336</pub-id>
</mixed-citation></ref><ref id="cit0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dominy</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Lynch</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Ermini</surname>
<given-names>F</given-names></string-name>, et al</person-group>. <article-title>Porphyromonas gingivalis in Alzheimer&#x02019;s disease brains: evidence for disease causation and treatment with small-molecule inhibitors</article-title>. <source>Sci Adv</source>. <year>2019</year>;<volume>5</volume>(<issue>1</issue>):<fpage>eaau3333</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.aau3333</pub-id><pub-id pub-id-type="pmid">30746447</pub-id>
</mixed-citation></ref><ref id="cit0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Botelho</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Machado</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Leira</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Economic burden of periodontitis in the United States and Europe: an updated estimation</article-title>. <source>J Periodontol</source>. <year>2022</year>;<volume>93</volume>(<issue>3</issue>):<fpage>373</fpage>&#x02013;<lpage>379</lpage>. doi: <pub-id pub-id-type="doi">10.1002/JPER.21-0111</pub-id><pub-id pub-id-type="pmid">34053082</pub-id>
</mixed-citation></ref><ref id="cit0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindhe</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Westfelt</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Nyman</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Long&#x02010;term effect of surgical/non&#x02010;surgical treatment of periodontal disease</article-title>. <source>J Clin Periodontol</source>. <year>1984</year>;<volume>11</volume>(<issue>7</issue>):<fpage>448</fpage>&#x02013;<lpage>458</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-051X.1984.tb01344.x</pub-id><pub-id pub-id-type="pmid">6378986</pub-id>
</mixed-citation></ref><ref id="cit0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanz-Mart&#x000ed;n</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Cha</surname>
<given-names>J-K</given-names></string-name>, <string-name><surname>Yoon</surname>
<given-names>S-W</given-names></string-name>, et al</person-group>. <article-title>Long-term assessment of periodontal disease progression after surgical or non-surgical treatment: a systematic review</article-title>. <source>J Periodontal Implant Sci</source>. <year>2019</year>;<volume>49</volume>(<issue>2</issue>):<fpage>60</fpage>&#x02013;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.5051/jpis.2019.49.2.60</pub-id><pub-id pub-id-type="pmid">31098328</pub-id>
</mixed-citation></ref><ref id="cit0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Axelsson</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lindhe</surname>
<given-names>J</given-names></string-name></person-group>. <article-title>The significance of maintenance care in the treatment of periodontal disease</article-title>. <source>J Clin Periodontol</source>. <year>1981</year>;<volume>8</volume>(<issue>4</issue>):<fpage>281</fpage>&#x02013;<lpage>294</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-051X.1981.tb02039.x</pub-id><pub-id pub-id-type="pmid">6947992</pub-id>
</mixed-citation></ref><ref id="cit0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byrne</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Darby</surname>
<given-names>IB</given-names></string-name>, et al</person-group>. <article-title>Progression of chronic periodontitis can be predicted by the levels of porphyromonas gingivalis and treponema denticola in subgingival plaque</article-title>. <source>Oral Microbiol Immunol</source>. <year>2009</year>;<volume>24</volume>(<issue>6</issue>):<fpage>469</fpage>&#x02013;<lpage>477</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1399-302X.2009.00544.x</pub-id><pub-id pub-id-type="pmid">19832799</pub-id>
</mixed-citation></ref><ref id="cit0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cobb</surname>
<given-names>CM</given-names></string-name></person-group>. <article-title>Non&#x02010;surgical pocket therapy: mechanical</article-title>. <source>Ann Periodontol</source>. <year>1996</year>;<volume>1</volume>(<issue>1</issue>):<fpage>443</fpage>&#x02013;<lpage>490</lpage>. doi: <pub-id pub-id-type="doi">10.1902/annals.1996.1.1.443</pub-id><pub-id pub-id-type="pmid">9118268</pub-id>
</mixed-citation></ref><ref id="cit0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heitz&#x02010;Mayfield</surname>
<given-names>LJA</given-names></string-name>, <string-name><surname>Lang</surname>
<given-names>NP</given-names></string-name></person-group>. <article-title>Surgical and nonsurgical periodontal therapy. Learned and unlearned concepts</article-title>. <source>Periodontol 2000</source>. <year>2013</year>;<volume>62</volume>(<issue>1</issue>):<fpage>218</fpage>&#x02013;<lpage>231</lpage>. doi: <pub-id pub-id-type="doi">10.1111/prd.12008</pub-id><pub-id pub-id-type="pmid">23574468</pub-id>
</mixed-citation></ref><ref id="cit0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Greenstein</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>Nonsurgical periodontal therapy in 2000: a literature review</article-title>. <source>J Am Dent Assoc</source>. <year>2000</year>;<volume>131</volume>(<issue>11</issue>):<fpage>1580</fpage>&#x02013;<lpage>1592</lpage>. doi: <pub-id pub-id-type="doi">10.14219/jada.archive.2000.0087</pub-id><pub-id pub-id-type="pmid">11103577</pub-id>
</mixed-citation></ref><ref id="cit0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van der Weijden</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Timmerman</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>A systematic review on the clinical efficacy of subgingival debridement in the treatment of chronic periodontitis</article-title>. <source>J Clin Periodontol</source>. <year>2002</year>;<volume>29</volume>(<issue>s3</issue>):<fpage>55</fpage>&#x02013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1034/j.1600-051X.29.s3.3.x</pub-id><pub-id pub-id-type="pmid">12787207</pub-id>
</mixed-citation></ref><ref id="cit0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rabbani</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Ash</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Caffesse</surname>
<given-names>RG</given-names></string-name></person-group>. <article-title>The effectiveness of subgingival scaling and root planing in calculus removal</article-title>. <source>J Periodontol</source>. <year>1981</year>;<volume>52</volume>(<issue>3</issue>):<fpage>119</fpage>&#x02013;<lpage>123</lpage>. doi: <pub-id pub-id-type="doi">10.1902/jop.1981.52.3.119</pub-id><pub-id pub-id-type="pmid">7014822</pub-id>
</mixed-citation></ref><ref id="cit0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sherman</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hutchens</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jewson</surname>
<given-names>L</given-names></string-name></person-group>. <article-title>The effectiveness of subgingival scaling and root planing II. Clinical responses related to residual calculus</article-title>. <source>J Periodontol</source>. <year>1990</year>;<volume>61</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1902/jop.1990.61.1.9</pub-id><pub-id pub-id-type="pmid">2179516</pub-id>
</mixed-citation></ref><ref id="cit0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Retamal-Valdes</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Teughels</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Oliveira</surname>
<given-names>LM</given-names></string-name>, et al</person-group>. <article-title>Clinical, microbiological, and immunological effects of systemic probiotics in periodontal treatment: study protocol for a randomized controlled trial</article-title>. <source>Trials</source>. <year>2021</year>;<volume>22</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s13063-021-05246-0</pub-id><pub-id pub-id-type="pmid">33397449</pub-id>
</mixed-citation></ref><ref id="cit0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Teughels</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Feres</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Oud</surname>
<given-names>V</given-names></string-name>, et al</person-group>. <article-title>Adjunctive effect of systemic antimicrobials in periodontitis therapy: a systematic review and meta&#x02010;analysis</article-title>. <source>J Clin Periodontol</source>. <year>2020</year>;<volume>47</volume>(<issue>S22</issue>):<fpage>257</fpage>&#x02013;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcpe.13264</pub-id></mixed-citation></ref><ref id="cit0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Belibasakis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ivanovski</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Community dynamics of subgingival microbiome in periodontitis and targets for microbiome modulation therapy</article-title>. <source>Crit Rev Microbiol</source>. <year>2022</year>;<volume>49</volume>(<issue>6</issue>):<fpage>726</fpage>&#x02013;<lpage>738</lpage>. doi: <pub-id pub-id-type="doi">10.1080/1040841X.2022.2133594</pub-id><pub-id pub-id-type="pmid">36260510</pub-id>
</mixed-citation></ref><ref id="cit0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byrne</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Adams</surname>
<given-names>GG</given-names></string-name>, et al</person-group>. <article-title>Microbiome profiles of non-responding and responding paired periodontitis sites within the same participants following non-surgical treatment</article-title>. <source>J Oral Microbiol</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>2043595</fpage>. doi: <pub-id pub-id-type="doi">10.1080/20002297.2022.2043595</pub-id><pub-id pub-id-type="pmid">35295980</pub-id>
</mixed-citation></ref><ref id="cit0024"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>El-Bagoory</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>El-Guindy</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Shoukheba</surname>
<given-names>MM</given-names></string-name>, et al</person-group>. <article-title>The adjunctive effect of probiotics to nonsurgical treatment of chronic periodontitis: a randomized controlled clinical trial</article-title>. <source>J Indian Soc Periodontol</source>. <year>2021</year>;<volume>25</volume>(<issue>6</issue>):<fpage>525</fpage>. doi: <pub-id pub-id-type="doi">10.4103/jisp.jisp_114_21</pub-id><pub-id pub-id-type="pmid">34898919</pub-id>
</mixed-citation></ref><ref id="cit0025"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Curtis</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Diaz</surname>
<given-names>PI</given-names></string-name>, <string-name><surname>Van Dyke</surname>
<given-names>TE</given-names></string-name>, et al</person-group>. <article-title>The role of the microbiota in periodontal disease</article-title>. <source>Periodontol 2000</source>. <year>2020</year>;<volume>83</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1111/prd.12296</pub-id><pub-id pub-id-type="pmid">32385883</pub-id>
</mixed-citation></ref><ref id="cit0026"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bostanci</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Belibasakis</surname>
<given-names>GN</given-names></string-name></person-group>. <article-title>Porphyromonas gingivalis: an invasive and evasive opportunistic oral pathogen</article-title>. <source>FEMS Microbiol Lett</source>. <year>2012</year>;<volume>333</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6968.2012.02579.x</pub-id><pub-id pub-id-type="pmid">22530835</pub-id>
</mixed-citation></ref><ref id="cit0027"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Socransky</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Haffajee</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>Cugini</surname>
<given-names>MA</given-names></string-name>, et al</person-group>. <article-title>Microbial complexes in subgingival plaque</article-title>. <source>J Clin Periodontol</source>. <year>1998</year>;<volume>25</volume>(<issue>2</issue>):<fpage>134</fpage>&#x02013;<lpage>144</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-051X.1998.tb02419.x</pub-id><pub-id pub-id-type="pmid">9495612</pub-id>
</mixed-citation></ref><ref id="cit0028"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajishengallis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Darveau</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Curtis</surname>
<given-names>MA</given-names></string-name></person-group>. <article-title>The keystone-pathogen hypothesis</article-title>. <source>Nat Rev Microbiol</source>. <year>2012</year>;<volume>10</volume>(<issue>10</issue>):<fpage>717</fpage>&#x02013;<lpage>725</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro2873</pub-id><pub-id pub-id-type="pmid">22941505</pub-id>
</mixed-citation></ref><ref id="cit0029"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajishengallis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Lamont</surname>
<given-names>RJ</given-names></string-name></person-group>. <article-title>Dancing with the stars: how choreographed bacterial interactions dictate nososymbiocity and give rise to keystone pathogens, accessory pathogens, and pathobionts</article-title>. <source>Trends Microbiol</source>. <year>2016</year>;<volume>24</volume>(<issue>6</issue>):<fpage>477</fpage>&#x02013;<lpage>489</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2016.02.010</pub-id><pub-id pub-id-type="pmid">26968354</pub-id>
</mixed-citation></ref><ref id="cit0030"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajishengallis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Lamont</surname>
<given-names>RJ</given-names></string-name></person-group>. <article-title>Polymicrobial communities in periodontal disease: their quasi&#x02010;organismal nature and dialogue with the host</article-title>. <source>Periodontol 2000</source>. <year>2021</year>;<volume>86</volume>(<issue>1</issue>):<fpage>210</fpage>&#x02013;<lpage>230</lpage>. doi: <pub-id pub-id-type="doi">10.1111/prd.12371</pub-id><pub-id pub-id-type="pmid">33690950</pub-id>
</mixed-citation></ref><ref id="cit0031"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Penesyan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Paulsen</surname>
<given-names>IT</given-names></string-name>, <string-name><surname>Kjelleberg</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Three faces of biofilms: a microbial lifestyle, a nascent multicellular organism, and an incubator for diversity</article-title>. <source>NPJ Biofilms Microbiomes</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>80</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41522-021-00251-2</pub-id><pub-id pub-id-type="pmid">34759294</pub-id>
</mixed-citation></ref><ref id="cit0032"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Barraza</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Arthur</surname>
<given-names>RA</given-names></string-name>, et al</person-group>. <article-title>Spatial mapping of polymicrobial communities reveals a precise biogeography associated with human dental caries</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>(<issue>22</issue>):<fpage>12375</fpage>&#x02013;<lpage>12386</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1919099117</pub-id><pub-id pub-id-type="pmid">32424080</pub-id>
</mixed-citation></ref><ref id="cit0033"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ibberson</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Barraza</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Holmes</surname>
<given-names>AL</given-names></string-name>, et al</person-group>. <article-title>Precise spatial structure impacts antimicrobial susceptibility of S. aureus in polymicrobial wound infections</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2022</year>;<volume>119</volume>(<issue>51</issue>):<fpage>e2212340119</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2212340119</pub-id><pub-id pub-id-type="pmid">36520668</pub-id>
</mixed-citation></ref><ref id="cit0034"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mondrag&#x000f3;n-Palomino</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Poceviciute</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lignell</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Three-dimensional imaging for the quantification of spatial patterns in microbiota of the intestinal mucosa</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2022</year>;<volume>119</volume>(<issue>18</issue>):<fpage>e2118483119</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2118483119</pub-id><pub-id pub-id-type="pmid">35476531</pub-id>
</mixed-citation></ref><ref id="cit0035"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kolenbrander</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Palmer</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Periasamy</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Oral multispecies biofilm development and the key role of cell&#x02013;cell distance</article-title>. <source>Nat Rev Microbiol</source>. <year>2010</year>;<volume>8</volume>(<issue>7</issue>):<fpage>471</fpage>&#x02013;<lpage>480</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro2381</pub-id><pub-id pub-id-type="pmid">20514044</pub-id>
</mixed-citation></ref><ref id="cit0036"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuboniwa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lamont</surname>
<given-names>RJ</given-names></string-name></person-group>. <article-title>Heterotypic streptococcus gordonii-porphyromonas gingivalis communities: formation, gene regulation, and development</article-title>. <source>Oral Microb Communities</source>. <year>2011</year>:<fpage>313</fpage>&#x02013;<lpage>P1</lpage>.</mixed-citation></ref><ref id="cit0037"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sakanaka</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kuboniwa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shimma</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Fusobacterium nucleatum metabolically integrates commensals and pathogens in oral biofilms</article-title>. <source>mSystems</source>. <year>2022</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e00170</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1128/msystems.00170-22</pub-id><pub-id pub-id-type="pmid">35852319</pub-id>
</mixed-citation></ref><ref id="cit0038"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamaguchi-Kuroda</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kikuchi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kokubu</surname>
<given-names>E</given-names></string-name>, et al</person-group>. <article-title>Porphyromonas gingivalis diffusible signaling molecules enhance fusobacterium nucleatum biofilm formation via gene expression modulation</article-title>. <source>J Oral Microbiol</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2165001</fpage>. doi: <pub-id pub-id-type="doi">10.1080/20002297.2023.2165001</pub-id><pub-id pub-id-type="pmid">36687169</pub-id>
</mixed-citation></ref><ref id="cit0039"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Seers</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>SG</given-names></string-name>, et al</person-group>. <article-title>Porphyromonas gingivalis and treponema denticola exhibit metabolic symbioses</article-title>. <source>PLOS Pathog</source>. <year>2014</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e1003955</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1003955</pub-id><pub-id pub-id-type="pmid">24603978</pub-id>
</mixed-citation></ref><ref id="cit0040"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ng</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Slakeski</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Butler</surname>
<given-names>CA</given-names></string-name>, et al</person-group>. <article-title>The role of treponema denticola motility in synergistic biofilm formation with porphyromonas gingivalis</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2019</year>;<volume>9</volume>:<fpage>432</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2019.00432</pub-id><pub-id pub-id-type="pmid">31921707</pub-id>
</mixed-citation></ref><ref id="cit0041"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y-Y</given-names></string-name>, et al</person-group>. <article-title>Porphyromonas gingivalis and treponema denticola synergistic polymicrobial biofilm development</article-title>. <source>PLOS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>8</issue>):<fpage>e71727</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0071727</pub-id><pub-id pub-id-type="pmid">23990979</pub-id>
</mixed-citation></ref><ref id="cit0042"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zainal-Abidin</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Veith</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>SG</given-names></string-name>, et al</person-group>. <article-title>Differential proteomic analysis of a polymicrobial biofilm</article-title>. <source>J Proteome Res</source>. <year>2012</year>;<volume>11</volume>(<issue>9</issue>):<fpage>4449</fpage>&#x02013;<lpage>4464</lpage>. doi: <pub-id pub-id-type="doi">10.1021/pr300201c</pub-id><pub-id pub-id-type="pmid">22808953</pub-id>
</mixed-citation></ref><ref id="cit0043"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>BR</given-names></string-name>, et al</person-group>. <article-title>Critical analysis in the advancement of cell-based assays for botulinum neurotoxin</article-title>. <source>Crit Rev Microbiol</source>. <year>2023</year>;<volume>49</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1080/1040841X.2022.2035315</pub-id><pub-id pub-id-type="pmid">35212259</pub-id>
</mixed-citation></ref><ref id="cit0044"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dashper</surname>
<given-names>S</given-names></string-name>, <string-name><surname>O&#x02019;Brien-Simpson</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>SW</given-names></string-name>, et al</person-group>. <article-title>Oxantel disrupts polymicrobial biofilm development of periodontal pathogens</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>1</issue>):<fpage>378</fpage>&#x02013;<lpage>385</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01375-13</pub-id><pub-id pub-id-type="pmid">24165189</pub-id>
</mixed-citation></ref><ref id="cit0045"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brennan</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Garrett</surname>
<given-names>WS</given-names></string-name></person-group>. <article-title>Fusobacterium nucleatum&#x02014;symbiont, opportunist and oncobacterium</article-title>. <source>Nat Rev Microbiol</source>. <year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>156</fpage>&#x02013;<lpage>166</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-018-0129-6</pub-id><pub-id pub-id-type="pmid">30546113</pub-id>
</mixed-citation></ref><ref id="cit0046"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamont</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Fitzsimonds</surname>
<given-names>ZR</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>Role of porphyromonas gingivalis in oral and orodigestive squamous cell carcinoma</article-title>. <source>Periodontol 2000</source>. <year>2022</year>;<volume>89</volume>(<issue>1</issue>):<fpage>154</fpage>&#x02013;<lpage>165</lpage>. doi: <pub-id pub-id-type="doi">10.1111/prd.12425</pub-id><pub-id pub-id-type="pmid">35244980</pub-id>
</mixed-citation></ref><ref id="cit0047"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname>
<given-names>YW</given-names></string-name></person-group>. <article-title>Fusobacterium nucleatum: a commensal-turned pathogen</article-title>. <source>Curr Opin Microbiol</source>. <year>2015</year>;<volume>23</volume>:<fpage>141</fpage>&#x02013;<lpage>147</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2014.11.013</pub-id><pub-id pub-id-type="pmid">25576662</pub-id>
</mixed-citation></ref><ref id="cit0048"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gully</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bright</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Marino</surname>
<given-names>V</given-names></string-name>, et al</person-group>. <article-title>Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis</article-title>. <source>PLOS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e100838</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0100838</pub-id><pub-id pub-id-type="pmid">24959715</pub-id>
</mixed-citation></ref><ref id="cit0049"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nara</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Sindelar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Penn</surname>
<given-names>MS</given-names></string-name>, et al</person-group>. <article-title>Porphyromonas gingivalis outer membrane vesicles as the major driver of and explanation for neuropathogenesis, the cholinergic hypothesis, iron dyshomeostasis, and salivary lactoferrin in Alzheimer&#x02019;s disease</article-title>. <source>J Ailzhemier&#x02019; Dis</source>. <year>2021</year>;<volume>82</volume>(<issue>4</issue>):<fpage>1417</fpage>&#x02013;<lpage>1450</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-210448</pub-id></mixed-citation></ref><ref id="cit0050"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pisani</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Pisani</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Arcangeli</surname>
<given-names>F</given-names></string-name>, et al</person-group>. <article-title>Locus coeruleus dysfunction and trigeminal mesencephalic nucleus degeneration: a cue for periodontal infection mediated damage in Alzheimer&#x02019;s disease?</article-title>
<source>Int J Environ Res Public Health</source>. <year>2023</year>;<volume>20</volume>(<issue>2</issue>):<fpage>1007</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijerph20021007</pub-id><pub-id pub-id-type="pmid">36673763</pub-id>
</mixed-citation></ref><ref id="cit0051"><label>[51]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Hendrix</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Hatfull</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Ford</surname>
<given-names>ME</given-names></string-name>, et al</person-group>. <source>Evolutionary relationships among diverse bacteriophages and prophages: all the world&#x02019;s a phage, <italic toggle="yes">in horizontal gene transfer</italic></source>. <publisher-loc>Massachusetts USA</publisher-loc>: <publisher-name>Academic Press Cambridge</publisher-name>; <year>2002</year>. p. <fpage>133</fpage>&#x02013;<lpage>VI</lpage>.</mixed-citation></ref><ref id="cit0052"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turner</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kropinski</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Adriaenssens</surname>
<given-names>EM</given-names></string-name></person-group>. <article-title>A roadmap for genome-based phage taxonomy</article-title>. <source>Viruses</source>. <year>2021</year>;<volume>13</volume>(<issue>3</issue>):<fpage>506</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13030506</pub-id><pub-id pub-id-type="pmid">33803862</pub-id>
</mixed-citation></ref><ref id="cit0053"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schubert</surname>
<given-names>BD</given-names></string-name>, <string-name><surname>Ku</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kabwe</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Effects of Klebsiella pneumoniae bacteriophages on IRAK3 knockdown/knockout THP-1 monocyte cell lines</article-title>. <source>Viruses</source>. <year>2022</year>;<volume>14</volume>(<issue>11</issue>):<fpage>2582</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v14112582</pub-id><pub-id pub-id-type="pmid">36423191</pub-id>
</mixed-citation></ref><ref id="cit0054"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kabwe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting fusobacterium nucleatum biofilms</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>9107</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-45549-6</pub-id><pub-id pub-id-type="pmid">31235721</pub-id>
</mixed-citation></ref><ref id="cit0055"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kabwe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Speirs</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Novel bacteriophages capable of disrupting biofilms from clinical strains of aeromonas hydrophila</article-title>. <source>Front Microbiol</source>. <year>2020</year>;<volume>11</volume>:<fpage>194</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2020.00194</pub-id><pub-id pub-id-type="pmid">32117183</pub-id>
</mixed-citation></ref><ref id="cit0056"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kivel&#x000e4;</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Kalkkinen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bamford</surname>
<given-names>DH</given-names></string-name></person-group>. <article-title>Bacteriophage PM2&#x000a0;has a protein capsid surrounding a spherical proteinaceous lipid core</article-title>. <source>J Virol</source>. <year>2002</year>;<volume>76</volume>(<issue>16</issue>):<fpage>8169</fpage>&#x02013;<lpage>8178</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.76.16.8169-8178.2002</pub-id><pub-id pub-id-type="pmid">12134022</pub-id>
</mixed-citation></ref><ref id="cit0057"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Philippe</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Krupovic</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jaomanjaka</surname>
<given-names>F</given-names></string-name>, et al</person-group>. <article-title>Bacteriophage GC1, a novel tectivirus infecting gluconobacter cerinus, an acetic acid bacterium associated with wine-making</article-title>. <source>Viruses</source>. <year>2018</year>;<volume>10</volume>(<issue>1</issue>):<fpage>39</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v10010039</pub-id><pub-id pub-id-type="pmid">29337868</pub-id>
</mixed-citation></ref><ref id="cit0058"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gourlay</surname>
<given-names>RN</given-names></string-name></person-group>. <article-title>Mycoplasmatales virus-laidlawii 2, a new virus isolated from acholeplasma laidlawii</article-title>. <source>J Gen Virol</source>. <year>1971</year>;<volume>12</volume>(<issue>1</issue>):<fpage>65</fpage>&#x02013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-12-1-65</pub-id><pub-id pub-id-type="pmid">4106810</pub-id>
</mixed-citation></ref><ref id="cit0059"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ackermann</surname>
<given-names>H-W</given-names></string-name></person-group>. <article-title>Classification of bacteriophages</article-title>. <source>The Bacteriophages</source>. <year>2006</year>;<volume>2</volume>:<fpage>8</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="cit0060"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mavrich</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Hatfull</surname>
<given-names>GF</given-names></string-name></person-group>. <article-title>Bacteriophage evolution differs by host, lifestyle and genome</article-title>. <source>Nat Microbiol</source>. <year>2017</year>;<volume>2</volume>(<issue>9</issue>):<fpage>17112</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.112</pub-id><pub-id pub-id-type="pmid">28692019</pub-id>
</mixed-citation></ref><ref id="cit0061"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szekely</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Breitbart</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Millard</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Single-stranded DNA phages: from early molecular biology tools to recent revolutions in environmental microbiology</article-title>. <source>FEMS Microbiol Lett</source>. <year>2016</year>;<volume>363</volume>(<issue>6</issue>):<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1093/femsle/fnw027</pub-id></mixed-citation></ref><ref id="cit0062"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gallardo</surname>
<given-names>VA</given-names></string-name>, <string-name><surname>Espinoza</surname>
<given-names>C</given-names></string-name></person-group>. <article-title>New communities of large filamentous sulfur bacteria in the eastern South Pacific</article-title>. <source>Int Microbiol</source>. <year>2007</year>;<volume>10</volume>(<issue>2</issue>):<fpage>97</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">17661287</pub-id>
</mixed-citation></ref><ref id="cit0063"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>P&#x000e9;rez-Brocal</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Gil</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ramos</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>A small microbial genome: the end of a long symbiotic relationship?</article-title>
<source>Science</source>. <year>2006</year>;<volume>314</volume>(<issue>5797</issue>):<fpage>312</fpage>&#x02013;<lpage>313</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1130441</pub-id><pub-id pub-id-type="pmid">17038625</pub-id>
</mixed-citation></ref><ref id="cit0064"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dyson</surname>
<given-names>ZA</given-names></string-name>, <string-name><surname>Tucci</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Seviour</surname>
<given-names>RJ</given-names></string-name>, et al</person-group>. <article-title>Three of a kind: genetically similar tsukamurella phages TIN2, TIN3, and TIN4</article-title>. <source>Appl Environ Microbiol</source>. <year>2015</year>;<volume>81</volume>(<issue>19</issue>):<fpage>6767</fpage>&#x02013;<lpage>6772</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.01145-15</pub-id><pub-id pub-id-type="pmid">26187971</pub-id>
</mixed-citation></ref><ref id="cit0065"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varga</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pantu&#x000b0;&#x0010d;ek</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ru&#x000b0;&#x0017e;i&#x0010d;kov&#x000e1;</surname>
<given-names>V</given-names></string-name>, et al</person-group>. <article-title>Molecular characterization of a new efficiently transducing bacteriophage identified in meticillin-resistant staphylococcus aureus</article-title>. <source>J Gen Virol</source>. <year>2016</year>;<volume>97</volume>(<issue>1</issue>):<fpage>258</fpage>&#x02013;<lpage>268</lpage>. doi: <pub-id pub-id-type="doi">10.1099/jgv.0.000329</pub-id><pub-id pub-id-type="pmid">26537974</pub-id>
</mixed-citation></ref><ref id="cit0066"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chatterjee</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Datta</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Bacteriophages and its applications: an overview</article-title>. <source>Folia Microbiol (Praha)</source>. <year>2017</year>;<volume>62</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12223-016-0471-x</pub-id><pub-id pub-id-type="pmid">27718043</pub-id>
</mixed-citation></ref><ref id="cit0067"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname>
<given-names>HL</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Catmull</surname>
<given-names>DV</given-names></string-name>, et al</person-group>. <article-title>Treponema denticola biofilm-induced expression of a bacteriophage, toxin&#x02013;antitoxin systems and transposases</article-title>. <source>Microbiol</source>. <year>2010</year>;<volume>156</volume>(<issue>3</issue>):<fpage>774</fpage>&#x02013;<lpage>788</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.033654-0</pub-id></mixed-citation></ref><ref id="cit0068"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fenton</surname>
<given-names>M</given-names></string-name>, <string-name><surname>McAuliffe</surname>
<given-names>O</given-names></string-name>, <string-name><surname>O&#x02019;Mahony</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Recombinant bacteriophage lysins as antibacterials</article-title>. <source>Bioengineered Bugs</source>. <year>2010</year>;<volume>1</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.4161/bbug.1.1.9818</pub-id><pub-id pub-id-type="pmid">21327123</pub-id>
</mixed-citation></ref><ref id="cit0069"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dyson</surname>
<given-names>ZA</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Farrar</surname>
<given-names>B</given-names></string-name>, et al</person-group>. <article-title>Locating and activating molecular &#x02018;time bombs&#x02019;: nduction of mycolata prophages</article-title>. <source>PLOS ONE</source>. <year>2016</year>;<volume>11</volume>(<issue>8</issue>):<fpage>e0159957</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0159957</pub-id><pub-id pub-id-type="pmid">27487243</pub-id>
</mixed-citation></ref><ref id="cit0070"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Gorman</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Donnelly</surname>
<given-names>RF</given-names></string-name>, et al</person-group>. <article-title>Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy</article-title>. <source>J Pharm Pharmacol</source>. <year>2011</year>;<volume>63</volume>(<issue>10</issue>):<fpage>1253</fpage>&#x02013;<lpage>1264</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.2042-7158.2011.01324.x</pub-id><pub-id pub-id-type="pmid">21899540</pub-id>
</mixed-citation></ref><ref id="cit0071"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoe</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Semler</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Goudie</surname>
<given-names>AD</given-names></string-name>, et al</person-group>. <article-title>Respirable bacteriophages for the treatment of bacterial lung infections</article-title>. <source>J Aerosol Med Pulm Drug Deliv</source>. <year>2013</year>;<volume>26</volume>(<issue>6</issue>):<fpage>317</fpage>&#x02013;<lpage>335</lpage>. doi: <pub-id pub-id-type="doi">10.1089/jamp.2012.1001</pub-id><pub-id pub-id-type="pmid">23597003</pub-id>
</mixed-citation></ref><ref id="cit0072"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Golkar</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Bagasra</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Pace</surname>
<given-names>DG</given-names></string-name></person-group>. <article-title>Bacteriophage therapy: a potential solution for the antibiotic resistance crisis</article-title>. <source>J Infect Dev Ctries</source>. <year>2014</year>;<volume>8</volume>(<issue>2</issue>):<fpage>129</fpage>&#x02013;<lpage>136</lpage>. doi: <pub-id pub-id-type="doi">10.3855/jidc.3573</pub-id><pub-id pub-id-type="pmid">24518621</pub-id>
</mixed-citation></ref><ref id="cit0073"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kropinski</surname>
<given-names>AM</given-names></string-name></person-group>. <article-title>Phage therapy -- everything old is new again</article-title>. <source>Can J Infect Dis Med Microbiol</source>. <year>2006</year>;<volume>17</volume>(<issue>5</issue>):<fpage>297</fpage>&#x02013;<lpage>306</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2006/329465</pub-id><pub-id pub-id-type="pmid">18382643</pub-id>
</mixed-citation></ref><ref id="cit0074"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordillo Altamirano</surname>
<given-names>FL</given-names></string-name>, <string-name><surname>Barr</surname>
<given-names>JJ</given-names></string-name></person-group>. <article-title>Phage therapy in the postantibiotic era</article-title>. <source>Clin Microbiol Rev</source>. <year>2019</year>;<volume>32</volume>(<issue>2</issue>):<fpage>2</fpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00066-18</pub-id></mixed-citation></ref><ref id="cit0075"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laxminarayan</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>The overlooked pandemic of antimicrobial resistance</article-title>. <source>Lancet</source>. <year>2022</year>;<volume>399</volume>(<issue>10325</issue>):<fpage>606</fpage>&#x02013;<lpage>607</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(22)00087-3</pub-id><pub-id pub-id-type="pmid">35065701</pub-id>
</mixed-citation></ref><ref id="cit0076"><label>[76]</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Phage Banks &#x00026; Collections | Bacteriophage.news</collab></person-group>. <year>2023</year>. <comment>Available from:</comment>
<ext-link xlink:href="https://www.bacteriophage.news/phage-banks-collections/" ext-link-type="uri">https://www.bacteriophage.news/phage-banks-collections/</ext-link></mixed-citation></ref><ref id="cit0077"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khatami</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Foley</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Warner</surname>
<given-names>MS</given-names></string-name>, et al</person-group>. <article-title>Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial</article-title>. <source>BMJ Open</source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e065401</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2022-065401</pub-id></mixed-citation></ref><ref id="cit0078"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abedon</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Kuhl</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Blasdel</surname>
<given-names>BG</given-names></string-name>, et al</person-group>. <article-title>Phage treatment of human infections</article-title>. <source>Bacteriophage</source>. <year>2011</year>;<volume>1</volume>(<issue>2</issue>):<fpage>66</fpage>&#x02013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.4161/bact.1.2.15845</pub-id><pub-id pub-id-type="pmid">22334863</pub-id>
</mixed-citation></ref><ref id="cit0079"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname>
<given-names>BK</given-names></string-name>, <string-name><surname>Abedon</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Loc-Carrillo</surname>
<given-names>C</given-names></string-name></person-group>. <article-title>Phage cocktails and the future of phage therapy</article-title>. <source>Future Microbiol</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>769</fpage>&#x02013;<lpage>783</lpage>. doi: <pub-id pub-id-type="doi">10.2217/fmb.13.47</pub-id><pub-id pub-id-type="pmid">23701332</pub-id>
</mixed-citation></ref><ref id="cit0080"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marongiu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Burkard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lauer</surname>
<given-names>UM</given-names></string-name>, et al</person-group>. <article-title>Reassessment of historical clinical trials supports the effectiveness of phage therapy</article-title>. <source>Clin Microbiol Rev</source>. <year>2022</year>;<volume>35</volume>(<issue>4</issue>):<fpage>e00062</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1128/cmr.00062-22</pub-id><pub-id pub-id-type="pmid">36069758</pub-id>
</mixed-citation></ref><ref id="cit0081"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stacey</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>De Soir</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>JD</given-names></string-name></person-group>. <article-title>The safety and efficacy of phage therapy: a systematic review of clinical and safety trials</article-title>. <source>Antibiotics (Basel)</source>. <year>2022</year>;<volume>11</volume>(<issue>10</issue>):<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11101340</pub-id></mixed-citation></ref><ref id="cit0082"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Batinovic</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wassef</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Knowler</surname>
<given-names>SA</given-names></string-name>, et al</person-group>. <article-title>Bacteriophages in natural and artificial environments</article-title>. <source>Pathogens</source>. <year>2019</year>;<volume>8</volume>(<issue>3</issue>):<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens8030100</pub-id><pub-id pub-id-type="pmid">30621134</pub-id>
</mixed-citation></ref><ref id="cit0083"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Safety assessment of staphylococcus phages of the family myoviridae based on complete genome sequences</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>41259</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep41259</pub-id><pub-id pub-id-type="pmid">28117392</pub-id>
</mixed-citation></ref><ref id="cit0084"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mattila</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ruotsalainen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Jalasvuori</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>On-Demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy</article-title>. <source>Front Microbiol</source>. <year>2015</year>;<volume>6</volume>:<fpage>1271</fpage>&#x02013;<lpage>1271</lpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2015.01271</pub-id><pub-id pub-id-type="pmid">26617601</pub-id>
</mixed-citation></ref><ref id="cit0085"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Howard-Varona</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hargreaves</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Abedon</surname>
<given-names>ST</given-names></string-name>, et al</person-group>. <article-title>Lysogeny in nature: mechanisms, impact and ecology of temperate phages</article-title>. <source>Isme J</source>. <year>2017</year>;<volume>11</volume>(<issue>7</issue>):<fpage>1511</fpage>&#x02013;<lpage>1520</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ismej.2017.16</pub-id><pub-id pub-id-type="pmid">28291233</pub-id>
</mixed-citation></ref><ref id="cit0086"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aslam</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Arshad</surname>
<given-names>MI</given-names></string-name>, <string-name><surname>Aslam</surname>
<given-names>MA</given-names></string-name>, et al</person-group>. <article-title>Bacteriophage proteome: insights and potentials of an alternate to antibiotics</article-title>. <source>Infect Dis Ther</source>. <year>2021</year>;<volume>10</volume>(<issue>3</issue>):<fpage>1171</fpage>&#x02013;<lpage>1193</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40121-021-00446-2</pub-id><pub-id pub-id-type="pmid">34170506</pub-id>
</mixed-citation></ref><ref id="cit0087"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szermer-Olearnik</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Boratynski</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Skurnik</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Removal of endotoxins from bacteriophage preparations by extraction with organic solvents</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0122672</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0122672</pub-id><pub-id pub-id-type="pmid">25811193</pub-id>
</mixed-citation></ref><ref id="cit0088"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Resch</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fehrenbacher</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Eisele</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Phage release from biofilm and planktonic staphylococcus aureus cells</article-title>. <source>FEMS Microbiol Lett</source>. <year>2005</year>;<volume>252</volume>(<issue>1</issue>):<fpage>89</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.femsle.2005.08.048</pub-id><pub-id pub-id-type="pmid">16213676</pub-id>
</mixed-citation></ref><ref id="cit0089"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rice</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Mikkelsen</surname>
<given-names>PJ</given-names></string-name>, et al</person-group>. <article-title>The biofilm life cycle and virulence of pseudomonas aeruginosa are dependent on a filamentous prophage</article-title>. <source>Isme J</source>. <year>2009</year>;<volume>3</volume>(<issue>3</issue>):<fpage>271</fpage>&#x02013;<lpage>282</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ismej.2008.109</pub-id><pub-id pub-id-type="pmid">19005496</pub-id>
</mixed-citation></ref><ref id="cit0090"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knecht</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Veljkovic</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fieseler</surname>
<given-names>L</given-names></string-name></person-group>. <article-title>Diversity and function of phage encoded depolymerases</article-title>. <source>Front Microbiol</source>. <year>2019</year>;<volume>10</volume>:<fpage>2949</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2019.02949</pub-id><pub-id pub-id-type="pmid">31998258</pub-id>
</mixed-citation></ref><ref id="cit0091"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gonz&#x000e1;lez</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fern&#x000e1;ndez</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Guti&#x000e9;rrez</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Analysis of different parameters affecting diffusion, propagation and survival of staphylophages in bacterial biofilms</article-title>. <source>Front Microbiol</source>. <year>2018</year>;<volume>9</volume>:<fpage>2348</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2018.02348</pub-id><pub-id pub-id-type="pmid">30323804</pub-id>
</mixed-citation></ref><ref id="cit0092"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quan</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hou</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>Water in bacterial biofilms: pores and channels, storage and transport functions</article-title>. <source>Crit Rev Microbiol</source>. <year>2022</year>;<volume>48</volume>(<issue>3</issue>):<fpage>283</fpage>&#x02013;<lpage>302</lpage>. doi: <pub-id pub-id-type="doi">10.1080/1040841X.2021.1962802</pub-id><pub-id pub-id-type="pmid">34411498</pub-id>
</mixed-citation></ref><ref id="cit0093"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kabwe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting fusobacterium nucleatum biofilms</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-45549-6</pub-id><pub-id pub-id-type="pmid">30626917</pub-id>
</mixed-citation></ref><ref id="cit0094"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khalifa</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Brosh</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gelman</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Targeting enterococcus faecalis biofilms with phage therapy</article-title>. <source>Appl Environ Microbiol</source>. <year>2015</year>;<volume>81</volume>(<issue>8</issue>):<fpage>2696</fpage>&#x02013;<lpage>2705</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.00096-15</pub-id><pub-id pub-id-type="pmid">25662974</pub-id>
</mixed-citation></ref><ref id="cit0095"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duplessis</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Biswas</surname>
<given-names>B</given-names></string-name></person-group>. <article-title>A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers</article-title>. <source>Antibiotics (Basel)</source>. <year>2020</year>;<volume>9</volume>(<issue>7</issue>):<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics9070377</pub-id></mixed-citation></ref><ref id="cit0096"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genevi&#x000e8;re</surname>
<given-names>J</given-names></string-name>, <string-name><surname>McCallin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Huttner</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>A systematic review of phage therapy applied to bone and joint infections: an analysis of success rates, treatment modalities and safety</article-title>. <source>EFORT Open Rev</source>. <year>2021</year>;<volume>6</volume>(<issue>12</issue>):<fpage>1148</fpage>&#x02013;<lpage>1156</lpage>. doi: <pub-id pub-id-type="doi">10.1302/2058-5241.6.210073</pub-id><pub-id pub-id-type="pmid">35003759</pub-id>
</mixed-citation></ref><ref id="cit0097"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tkhilaishvili</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Potapov</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Starck</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <article-title>Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German heart center berlin experience</article-title>. <source>J Heart Lung Transplant</source>. <year>2022</year>;<volume>41</volume>(<issue>5</issue>):<fpage>551</fpage>&#x02013;<lpage>555</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.healun.2022.01.018</pub-id><pub-id pub-id-type="pmid">35183435</pub-id>
</mixed-citation></ref><ref id="cit0098"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wright</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hawkins</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>&#x000c4;ngg&#x000e5;rd</surname>
<given-names>EE</given-names></string-name>, et al</person-group>. <article-title>A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant pseudomonas aeruginosa ; a preliminary report of efficacy</article-title>. <source>Clin Otolaryngol</source>. <year>2009</year>;<volume>34</volume>(<issue>4</issue>):<fpage>349</fpage>&#x02013;<lpage>357</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1749-4486.2009.01973.x</pub-id><pub-id pub-id-type="pmid">19673983</pub-id>
</mixed-citation></ref><ref id="cit0099"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clark</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>March</surname>
<given-names>JB</given-names></string-name></person-group>. <article-title>Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials</article-title>. <source>Trends Biotechnol</source>. <year>2006</year>;<volume>24</volume>(<issue>5</issue>):<fpage>212</fpage>&#x02013;<lpage>218</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tibtech.2006.03.003</pub-id><pub-id pub-id-type="pmid">16567009</pub-id>
</mixed-citation></ref><ref id="cit0100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dedrick</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Guerrero-Bustamante</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Garlena</surname>
<given-names>RA</given-names></string-name>, et al</person-group>. <article-title>Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant mycobacterium abscessus</article-title>. <source>Nat Med</source>. <year>2019</year>;<volume>25</volume>(<issue>5</issue>):<fpage>730</fpage>&#x02013;<lpage>733</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-019-0437-z</pub-id><pub-id pub-id-type="pmid">31068712</pub-id>
</mixed-citation></ref><ref id="cit0101"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yehl</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lemire</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>AC</given-names></string-name>, et al</person-group>. <article-title>Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis</article-title>. <source>Cell</source>. <year>2019</year>;<volume>179</volume>(<issue>2</issue>):<fpage>459</fpage>&#x02013;<lpage>469.e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2019.09.015</pub-id><pub-id pub-id-type="pmid">31585083</pub-id>
</mixed-citation></ref><ref id="cit0102"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ando</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lemire</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pires</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Engineering modular viral scaffolds for targeted bacterial population editing</article-title>. <source>Cell Syst</source>. <year>2015</year>;<volume>1</volume>(<issue>3</issue>):<fpage>187</fpage>&#x02013;<lpage>196</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cels.2015.08.013</pub-id><pub-id pub-id-type="pmid">26973885</pub-id>
</mixed-citation></ref><ref id="cit0103"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dunne</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rupf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Tala</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Reprogramming bacteriophage host range through structure-guided design of chimeric receptor binding proteins</article-title>. <source>Cell Rep</source>. <year>2019</year>;<volume>29</volume>(<issue>5</issue>):<fpage>1336</fpage>&#x02013;<lpage>1350.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2019.09.062</pub-id><pub-id pub-id-type="pmid">31665644</pub-id>
</mixed-citation></ref><ref id="cit0104"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lemon</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Kay</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Titus</surname>
<given-names>JK</given-names></string-name>, et al</person-group>. <article-title>Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018</article-title>. <source>J Microbiol</source>. <year>2019</year>;<volume>57</volume>(<issue>6</issue>):<fpage>532</fpage>&#x02013;<lpage>538</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12275-019-8686-6</pub-id><pub-id pub-id-type="pmid">31054139</pub-id>
</mixed-citation></ref><ref id="cit0105"><label>[105]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Channabasappa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chikkamadaiah</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Durgaiah</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Efficacy of chimeric ectolysin P128 in drug-resistant staphylococcus aureus bacteraemia in mice</article-title>. <source>J Antimicrob Chemother</source>. <year>2018</year>;<volume>73</volume>(<issue>12</issue>):<fpage>3398</fpage>&#x02013;<lpage>3404</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dky365</pub-id><pub-id pub-id-type="pmid">30215762</pub-id>
</mixed-citation></ref><ref id="cit0106"><label>[106]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cahill</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Young</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>Phage lysis: multiple genes for multiple barriers</article-title>. <source>Adv Virus Res</source>. <year>2019</year>;<volume>103</volume>:<fpage>33</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">30635077</pub-id>
</mixed-citation></ref><ref id="cit0107"><label>[107]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cochrane</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Manson McGuire</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Priest</surname>
<given-names>ME</given-names></string-name>, et al</person-group>. <article-title>Complete genome sequences and analysis of the fusobacterium nucleatum subspecies animalis 7&#x02013;1 bacteriophage &#x00278;Funu1 and &#x00278;Funu2</article-title>. <source>Anaerobe</source>. <year>2016</year>;<volume>38</volume>:<fpage>125</fpage>&#x02013;<lpage>129</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.anaerobe.2015.10.013</pub-id><pub-id pub-id-type="pmid">26545740</pub-id>
</mixed-citation></ref><ref id="cit0108"><label>[108]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matrishin</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Haase</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Dewhirst</surname>
<given-names>FE</given-names></string-name>, et al</person-group>. <article-title>Phages are unrecognized players in the ecology of the oral pathogen porphyromonas gingivalis</article-title>. <source>Microbiome</source>. <year>2023</year>;<volume>11</volume>(<issue>1</issue>):<fpage>161</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40168-023-01607-w</pub-id><pub-id pub-id-type="pmid">37491415</pub-id>
</mixed-citation></ref><ref id="cit0109"><label>[109]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname>
<given-names>GP</given-names></string-name></person-group>. <article-title>Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface</article-title>. <source>Science</source>. <year>1985</year>;<volume>228</volume>(<issue>4705</issue>):<fpage>1315</fpage>&#x02013;<lpage>1317</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.4001944</pub-id><pub-id pub-id-type="pmid">4001944</pub-id>
</mixed-citation></ref><ref id="cit0110"><label>[110]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jafari</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Abediankenari</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Phage particles as vaccine delivery vehicles: concepts, applications and prospects</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2015</year>;<volume>16</volume>(<issue>18</issue>):<fpage>8019</fpage>&#x02013;<lpage>8029</lpage>. doi: <pub-id pub-id-type="doi">10.7314/APJCP.2015.16.18.8019</pub-id><pub-id pub-id-type="pmid">26745034</pub-id>
</mixed-citation></ref><ref id="cit0111"><label>[111]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vandormael</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Verschueren</surname>
<given-names>P</given-names></string-name>, <string-name><surname>De Winter</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis</article-title>. <source>Immunol Res</source>. <year>2017</year>;<volume>65</volume>(<issue>1</issue>):<fpage>307</fpage>&#x02013;<lpage>325</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12026-016-8839-1</pub-id><pub-id pub-id-type="pmid">27503624</pub-id>
</mixed-citation></ref><ref id="cit0112"><label>[112]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Titus</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Kay</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Glaser</surname>
<given-names>CJJ</given-names></string-name></person-group>. <article-title>Application of phage display for the development of a novel inhibitor of PLA2 activity in Western cottonmouth venom</article-title>. <source>J Venom Res</source>. <year>2017</year>;<volume>8</volume>:<fpage>19</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">29285351</pub-id>
</mixed-citation></ref><ref id="cit0113"><label>[113]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bakhshinejad</surname>
<given-names>B</given-names></string-name></person-group>. <article-title>Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection</article-title>. <source>World J Gastroenterol</source>. <year>2014</year>;<volume>20</volume>(<issue>33</issue>):<fpage>11671</fpage>&#x02013;<lpage>11683</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v20.i33.11671</pub-id><pub-id pub-id-type="pmid">25206272</pub-id>
</mixed-citation></ref><ref id="cit0114"><label>[114]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luzar</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Strukelj</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Lunder</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Phage display peptide libraries in molecular allergology: from epitope mapping to mimotope-based immunotherapy</article-title>. <source>Allergy</source>. <year>2016</year>;<volume>71</volume>(<issue>11</issue>):<fpage>1526</fpage>&#x02013;<lpage>1532</lpage>. doi: <pub-id pub-id-type="doi">10.1111/all.12965</pub-id><pub-id pub-id-type="pmid">27341497</pub-id>
</mixed-citation></ref><ref id="cit0115"><label>[115]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szafra&#x00144;ski</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Slots</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stiesch</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>The human oral phageome</article-title>. <source>Periodontol 2000</source>. <year>2021</year>;<volume>86</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1111/prd.12363</pub-id><pub-id pub-id-type="pmid">33690937</pub-id>
</mixed-citation></ref><ref id="cit0116"><label>[116]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carr</surname>
<given-names>VR</given-names></string-name>, <string-name><surname>Shkoporov</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gomez-Cabrero</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>The human oral phageome is highly diverse and rich in jumbo phages</article-title>. <comment>bioRxiv</comment>. <year>2020</year>.</mixed-citation></ref><ref id="cit0117"><label>[117]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>A review and new perspective on oral bacteriophages: manifestations in the ecology of oral diseases</article-title>. <source>J Oral Microbiol</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.1080/20002297.2024.2344272</pub-id></mixed-citation></ref><ref id="cit0118"><label>[118]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xin Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zou</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>Guicong Ding &#x00026; Shan Jiang findings and methodologies in oral phageome research: a systematic review</article-title>. <source>J Oral Microbiol</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>). doi: <pub-id pub-id-type="doi">10.1080/20002297.2024.2417099</pub-id></mixed-citation></ref><ref id="cit0119"><label>[119]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Camargo</surname>
<given-names>AP</given-names></string-name>, <string-name><surname>Nayfach</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>I-MA</given-names></string-name>, et al</person-group>. <article-title>IMG/VR v4: an expanded database of uncultivated virus genomes within a framework of extensive functional, taxonomic, and ecological metadata</article-title>. <source>Nucleic Acids Res</source>. <year>2022</year>;<volume>51</volume>(<issue>D1</issue>):<fpage>D733</fpage>&#x02013;<lpage>D743</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkac1037</pub-id></mixed-citation></ref><ref id="cit0120"><label>[120]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baker</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Hendrickson</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>X</given-names></string-name>, et al</person-group>. <article-title>Klebsiella and providencia emerge as lone survivors following long-term starvation of oral microbiota</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2019</year>;<volume>116</volume>(<issue>17</issue>):<fpage>8499</fpage>&#x02013;<lpage>8504</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1820594116</pub-id><pub-id pub-id-type="pmid">30975748</pub-id>
</mixed-citation></ref><ref id="cit0121"><label>[121]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Olsen</surname>
<given-names>I</given-names></string-name></person-group>. <article-title>Porphyromonas gingivalis and its CRISPR-Cas system</article-title>. <source>J Oral Microbiol</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1638196</fpage>. doi: <pub-id pub-id-type="doi">10.1080/20002297.2019.1638196</pub-id><pub-id pub-id-type="pmid">31303969</pub-id>
</mixed-citation></ref><ref id="cit0122"><label>[122]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van der Ploeg</surname>
<given-names>JR</given-names></string-name></person-group>. <article-title>Analysis of CRISPR in streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages</article-title>. <source>Microbiol</source>. <year>2009</year>;<volume>155</volume>(<issue>6</issue>):<fpage>1966</fpage>&#x02013;<lpage>1976</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.027508-0</pub-id></mixed-citation></ref><ref id="cit0123"><label>[123]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winstanley</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Langille</surname>
<given-names>MGI</given-names></string-name>, <string-name><surname>Fothergill</surname>
<given-names>JL</given-names></string-name>, et al</person-group>. <article-title>Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the liverpool epidemic strain of pseudomonas aeruginosa</article-title>. <source>Genome Res</source>. <year>2009</year>;<volume>19</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1101/gr.086082.108</pub-id><pub-id pub-id-type="pmid">19047519</pub-id>
</mixed-citation></ref><ref id="cit0124"><label>[124]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matrishin</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Haase</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Dewhirst</surname>
<given-names>FE</given-names></string-name>, et al</person-group>. <article-title>Phages are unrecognized players in the ecology of the oral pathogen porphyromonas gingivalis</article-title>. <source><italic toggle="yes">Microbiome</italic></source>. <year>2023</year>;<volume>11</volume>(<issue>1</issue>):<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40168-023-01607-w</pub-id><pub-id pub-id-type="pmid">36670494</pub-id>
</mixed-citation></ref><ref id="cit0125"><label>[125]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dashper</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Seers</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>KH</given-names></string-name>, et al</person-group>. <article-title>Virulence factors of the oral spirochete treponema denticola</article-title>. <source>J Dent Res</source>. <year>2011</year>;<volume>90</volume>(<issue>6</issue>):<fpage>691</fpage>&#x02013;<lpage>703</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0022034510385242</pub-id><pub-id pub-id-type="pmid">20940357</pub-id>
</mixed-citation></ref><ref id="cit0126"><label>[126]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eggers</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Casjens</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hayes</surname>
<given-names>SF</given-names></string-name>, et al</person-group>. <article-title>Bacteriophages of spirochetes</article-title>. <source>J Mol Microbiol Biotechnol</source>. <year>2000</year>;<volume>2</volume>(<issue>4</issue>):<fpage>365</fpage>&#x02013;<lpage>373</lpage>.<pub-id pub-id-type="pmid">11075907</pub-id>
</mixed-citation></ref><ref id="cit0127"><label>[127]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kabwe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dashper</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bachrach</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?</article-title>
<source>FEMS Microbiol Rev</source>. <year>2021</year>;<volume>45</volume>(<issue>5</issue>):<fpage>fuab017</fpage>. doi: <pub-id pub-id-type="doi">10.1093/femsre/fuab017</pub-id><pub-id pub-id-type="pmid">33765142</pub-id>
</mixed-citation></ref><ref id="cit0128"><label>[128]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Q</given-names></string-name>, et al</person-group>. <article-title>Isolation and characterization of novel fusobacterium nucleatum bacteriophages</article-title>. <source>Front Microbiol</source>. <year>2022</year>;<volume>13</volume>:<fpage>945315</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2022.945315</pub-id><pub-id pub-id-type="pmid">36406437</pub-id>
</mixed-citation></ref><ref id="cit0129"><label>[129]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nang</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>YW</given-names></string-name>, <string-name><surname>Fabijan</surname>
<given-names>AP</given-names></string-name>, et al</person-group>. <article-title>Pharmacokinetics/Pharmacodynamics of phage therapy: a major hurdle to clinical translation</article-title>. <source>Clin Microbiol And Infect</source>. <year>2024</year>.</mixed-citation></ref><ref id="cit0130"><label>[130]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ryan</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Alkawareek</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Donnelly</surname>
<given-names>RF</given-names></string-name>, et al</person-group>. <article-title>Synergistic phage-antibiotic combinations for the control of escherichia coli biofilms in vitro</article-title>. <source>FEMS Immunol Med Microbiol</source>. <year>2012</year>;<volume>65</volume>(<issue>2</issue>):<fpage>395</fpage>&#x02013;<lpage>398</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-695X.2012.00977.x</pub-id><pub-id pub-id-type="pmid">22524448</pub-id>
</mixed-citation></ref><ref id="cit0131"><label>[131]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Green</surname>
<given-names>SI</given-names></string-name>, <string-name><surname>Min</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Phage-Antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry</article-title>. <source>MBio</source>. <year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>e01462</fpage>&#x02013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.01462-20</pub-id><pub-id pub-id-type="pmid">32753497</pub-id>
</mixed-citation></ref><ref id="cit0132"><label>[132]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neter</surname>
<given-names>E</given-names></string-name></person-group>. <article-title>Inhibitory effect of sulfamido compounds upon development and growth of phage-resistant bacteria</article-title>. <source>Proc Soc For Exp Biol Med</source>. <year>1941</year>;<volume>47</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.3181/00379727-47-13024</pub-id></mixed-citation></ref><ref id="cit0133"><label>[133]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname>
<given-names>BK</given-names></string-name>, <string-name><surname>Turner</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Phage treatment of an aortic graft infected with Pseudomonas aeruginosa</article-title>. <source>Evol Med Public Health</source>. <year>2018</year>;<volume>2018</volume>(<issue>1</issue>):<fpage>60</fpage>&#x02013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1093/emph/eoy005</pub-id><pub-id pub-id-type="pmid">29588855</pub-id>
</mixed-citation></ref><ref id="cit0134"><label>[134]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferry</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kolenda</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Batailler</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <article-title>Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S aureus prosthetic knee infection</article-title>. <source>Front Med (Lausanne)</source>. <year>2020</year>;<volume>7</volume>:<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2020.570572</pub-id><pub-id pub-id-type="pmid">32083086</pub-id>
</mixed-citation></ref><ref id="cit0135"><label>[135]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordillo Altamirano</surname>
<given-names>FL</given-names></string-name>, <string-name><surname>Kostoulias</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Subedi</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Phage-antibiotic combination is a superior treatment against acinetobacter baumannii in a preclinical study</article-title>. <source>EBioMedicine</source>. <year>2022</year>;<volume>80</volume>:<fpage>104045</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104045</pub-id><pub-id pub-id-type="pmid">35537278</pub-id>
</mixed-citation></ref><ref id="cit0136"><label>[136]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wohlfarth</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Feldm&#x000fc;ller</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Schneller</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>L-form conversion in gram-positive bacteria enables escape from phage infection</article-title>. <source>Nat Microbiol</source>. <year>2023</year>. doi: <pub-id pub-id-type="doi">10.1038/s41564-022-01317-3</pub-id></mixed-citation></ref><ref id="cit0137"><label>[137]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kortright</surname>
<given-names>KE</given-names></string-name>, <string-name><surname>Done</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>BK</given-names></string-name>, et al</person-group>. <article-title>Selection for phage eesistance reduces virulence of shigella flexneri</article-title>. <source>Appl Environ Microbiol</source>. <year>2022</year>;<volume>88</volume>(<issue>2</issue>):<fpage>e0151421</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.01514-21</pub-id><pub-id pub-id-type="pmid">34788068</pub-id>
</mixed-citation></ref><ref id="cit0138"><label>[138]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uchiyama</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shigehisa</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nasukawa</surname>
<given-names>T</given-names></string-name>, et al</person-group>. <article-title>Piperacillin and ceftazidime produce the strongest synergistic phage&#x02013;antibiotic effect in pseudomonas aeruginosa</article-title>. <source>Arch Virol</source>. <year>2018</year>;<volume>163</volume>(<issue>7</issue>):<fpage>1941</fpage>&#x02013;<lpage>1948</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00705-018-3811-0</pub-id><pub-id pub-id-type="pmid">29550930</pub-id>
</mixed-citation></ref><ref id="cit0139"><label>[139]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diallo</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Dublanchet</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Benefits of combined phage&#x02013;antibiotic therapy for the control of antibiotic-resistant bacteria: a literature review</article-title>. <source>Antibiotics (Basel)</source>. <year>2022</year>;<volume>11</volume>(<issue>7</issue>):<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics11070839</pub-id></mixed-citation></ref><ref id="cit0140"><label>[140]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brown</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Petrovski</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>Semi-Solid and solid dosage forms for the delivery of phage therapy to epithelia</article-title>. <source>Pharmaceuticals (Basel)</source>. <year>2018</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ph11010026</pub-id></mixed-citation></ref><ref id="cit0141"><label>[141]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Norris</surname>
<given-names>AH</given-names></string-name></person-group>. <article-title>Patent number: 4891210 - use of bacteriophages in dental hygiene</article-title>. <year>1990</year>.</mixed-citation></ref><ref id="cit0142"><label>[142]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tesson</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Herv&#x000e9;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mordret</surname>
<given-names>E</given-names></string-name>, et al</person-group>. <article-title>Systematic and quantitative view of the antiviral arsenal of prokaryotes</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>2561</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-022-30269-9</pub-id><pub-id pub-id-type="pmid">35538097</pub-id>
</mixed-citation></ref><ref id="cit0143"><label>[143]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bleriot</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Pacios</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Blasco</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Improving phage therapy by evasion of phage resistance mechanisms</article-title>. <source>JAC-Antimicrob Resist</source>. <year>2024</year>;<volume>6</volume>(<issue>1</issue>):<page-range>6(1</page-range>. doi: <pub-id pub-id-type="doi">10.1093/jacamr/dlae017</pub-id></mixed-citation></ref><ref id="cit0144"><label>[144]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Majewska</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ka&#x0017a;mierczak</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Lahutta</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Induction of phage-specific antibodies by two therapeutic staphylococcal bacteriophages administered per os</article-title>. <source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>2607</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.02607</pub-id><pub-id pub-id-type="pmid">31803179</pub-id>
</mixed-citation></ref><ref id="cit0145"><label>[145]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woof</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Russell</surname>
<given-names>MW</given-names></string-name></person-group>. <article-title>Structure and function relationships in IgA</article-title>. <source>Mucosal Immunol</source>. <year>2011</year>;<volume>4</volume>(<issue>6</issue>):<fpage>590</fpage>&#x02013;<lpage>597</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mi.2011.39</pub-id><pub-id pub-id-type="pmid">21937984</pub-id>
</mixed-citation></ref><ref id="cit0146"><label>[146]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ochs</surname>
<given-names>HD</given-names></string-name>, <string-name><surname>Davis</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Wedgwood</surname>
<given-names>RJ</given-names></string-name></person-group>. <article-title>Immunologic responses to bacteriophage &#x003d5;x 174 in immunodeficiency diseases</article-title>. <source>J Clin Invest</source>. <year>1971</year>;<volume>50</volume>(<issue>12</issue>):<fpage>2559</fpage>&#x02013;<lpage>2568</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI106756</pub-id><pub-id pub-id-type="pmid">5129308</pub-id>
</mixed-citation></ref><ref id="cit0147"><label>[147]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohan</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Zandi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Turner</surname>
<given-names>PE</given-names></string-name></person-group>. <article-title>Broadscale phage therapy is unlikely to select for widespread evolution of bacterial resistance to virus infection</article-title>. <source>Virus Evol</source>. <year>2020</year>;<volume>6</volume>(<issue>2</issue>):<fpage>veaa060</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ve/veaa060</pub-id><pub-id pub-id-type="pmid">33365149</pub-id>
</mixed-citation></ref><ref id="cit0148"><label>[148]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug Administration</collab></person-group>. <source>Setting endotoxin limits during development of investigational oncology drugs and biological products guidance for industry</source>. <publisher-name>U.S. Department of Health and Human Services, Editor</publisher-name>; <year>2020</year>. <comment>Available from:</comment>
<ext-link xlink:href="https://www.fda.gov/media/140410/download" ext-link-type="uri">https://www.fda.gov/media/140410/download</ext-link></mixed-citation></ref><ref id="cit0149"><label>[149]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jault</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Leclerc</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Jennes</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial</article-title>. <source>Lancet Infect Dis</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30482-1</pub-id><pub-id pub-id-type="pmid">30292481</pub-id>
</mixed-citation></ref><ref id="cit0150"><label>[150]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brives</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pourraz</surname>
<given-names>J</given-names></string-name></person-group>. <article-title>Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures</article-title>. <source>Palgrave Commun</source>. <year>2020</year>;<volume>6</volume>(<issue>1</issue>):<fpage>100</fpage>. doi: <pub-id pub-id-type="doi">10.1057/s41599-020-0478-4</pub-id></mixed-citation></ref><ref id="cit0151"><label>[151]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pirnay</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Ferry</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Resch</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>Recent progress toward the implementation of phage therapy in western medicine</article-title>. <source>FEMS Microbiol Reviews</source>. <year>2022</year>;<volume>46</volume>(<issue>1</issue>):<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.1093/femsre/fuab040</pub-id></mixed-citation></ref><ref id="cit0152"><label>[152]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pirnay</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Verbeken</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ceyssens</surname>
<given-names>P-J</given-names></string-name>, et al</person-group>. <article-title>The magistral phage</article-title>. <source>Viruses</source>. <year>2018</year>;<volume>10</volume>(<issue>2</issue>):<fpage>2</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v10020064</pub-id></mixed-citation></ref><ref id="cit0153"><label>[153]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fauconnier</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Phage therapy regulation: from night to dawn</article-title>. <source>Viruses</source>. <year>2019</year>;<volume>11</volume>(<issue>4</issue>):<fpage>352</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v11040352</pub-id><pub-id pub-id-type="pmid">30999559</pub-id>
</mixed-citation></ref><ref id="cit0154"><label>[154]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verbeken</surname>
<given-names>G</given-names></string-name>, <string-name><surname>De Vos</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Vaneechoutte</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>European regulatory conundrum of phage therapy</article-title>. <source>Future Microbiol</source>. <year>2007</year>;<volume>2</volume>(<issue>5</issue>):<fpage>485</fpage>&#x02013;<lpage>491</lpage>. doi: <pub-id pub-id-type="doi">10.2217/17460913.2.5.485</pub-id><pub-id pub-id-type="pmid">17927471</pub-id>
</mixed-citation></ref></ref-list></back></article>